{
    "641d8fd6690f196b51000041_0": [
        {
            "start_logit": 9.515625,
            "end_logit": 1.861328125,
            "text": "AQP4",
            "probability": 0.91748046875
        },
        {
            "start_logit": 9.515625,
            "end_logit": -0.55712890625,
            "text": "AQP4-IgG",
            "probability": 0.08209228515625
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.23046875,
            "text": "AQP4-IgG-positive",
            "probability": 0.00010311603546142578
        },
        {
            "start_logit": 9.515625,
            "end_logit": -7.3984375,
            "text": "AQP4-",
            "probability": 8.749961853027344e-05
        },
        {
            "start_logit": 9.515625,
            "end_logit": -9.859375,
            "text": "AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorde",
            "probability": 7.510185241699219e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -10.609375,
            "text": "AQP4-IgG-",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -11.109375,
            "text": "AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated dis",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -11.3203125,
            "text": "AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -11.3828125,
            "text": "AQP4-IgG-positive neuromyelitis optica spectrum disorder,",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 9.515625,
            "end_logit": -11.4296875,
            "text": "AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disord",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.6015625,
            "end_logit": -0.55712890625,
            "text": "IgG",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 1.861328125,
            "text": "multiple sclerosis, AQP4",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 1.861328125,
            "text": "sclerosis, AQP4",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -0.55712890625,
            "text": "-IgG",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -0.55712890625,
            "text": "multiple sclerosis, AQP4-IgG",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -0.55712890625,
            "text": "sclerosis, AQP4-IgG",
            "probability": 0.0
        },
        {
            "start_logit": -5.6015625,
            "end_logit": -7.23046875,
            "text": "IgG-positive",
            "probability": 0.0
        },
        {
            "start_logit": -5.6015625,
            "end_logit": -9.859375,
            "text": "IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorde",
            "probability": 0.0
        },
        {
            "start_logit": -8.75,
            "end_logit": -7.23046875,
            "text": "positive",
            "probability": 0.0
        },
        {
            "start_logit": -5.6015625,
            "end_logit": -10.609375,
            "text": "IgG-",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_1": [
        {
            "start_logit": 4.3828125,
            "end_logit": 2.427734375,
            "text": "The antibody against aquaporin-4 (AQP4)",
            "probability": 0.97265625
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -1.2392578125,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG)",
            "probability": 0.0248260498046875
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -4.67578125,
            "text": "The antibody against aquaporin-4 (AQP4",
            "probability": 0.0007982254028320312
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -4.703125,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004",
            "probability": 0.0007767677307128906
        },
        {
            "start_logit": -3.126953125,
            "end_logit": 2.427734375,
            "text": "antibody against aquaporin-4 (AQP4)",
            "probability": 0.0005311965942382812
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -7.72265625,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG",
            "probability": 3.7789344787597656e-05
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -7.98046875,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered",
            "probability": 2.9385089874267578e-05
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -8.359375,
            "text": "The antibody against aquaporin-4 (AQP4)-",
            "probability": 2.002716064453125e-05
        },
        {
            "start_logit": -3.126953125,
            "end_logit": -1.2392578125,
            "text": "antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG)",
            "probability": 1.3589859008789062e-05
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 2.427734375,
            "text": "aquaporin-4 (AQP4)",
            "probability": 1.049041748046875e-05
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -9.0546875,
            "text": "The",
            "probability": 1.0013580322265625e-05
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -9.515625,
            "text": "The antibody against aquaporin-4",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -9.5625,
            "text": "The antibody against aquaporin-4 (",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -10.0859375,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -8.171875,
            "end_logit": 2.427734375,
            "text": "AQP4)",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -10.3125,
            "text": "The antibody",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -1.5478515625,
            "end_logit": -4.703125,
            "text": "2004",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -10.828125,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 4.3828125,
            "end_logit": -11.0703125,
            "text": "The antibody against aquaporin-4 (AQP4)-immunoglobulin G",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -9.484375,
            "end_logit": 2.427734375,
            "text": "against aquaporin-4 (AQP4)",
            "probability": 9.5367431640625e-07
        }
    ],
    "641d8fd6690f196b51000041_2": [
        {
            "start_logit": 9.1171875,
            "end_logit": 0.39453125,
            "text": "Recently, several",
            "probability": 0.99609375
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -5.22265625,
            "text": "Recently",
            "probability": 0.0036067962646484375
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -8.9296875,
            "text": "Recently, several serum biomarkers have been proposed",
            "probability": 8.851289749145508e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -9.2109375,
            "text": "Recently,",
            "probability": 6.687641143798828e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -9.7265625,
            "text": "Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.",
            "probability": 3.987550735473633e-05
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": 0.39453125,
            "text": "several",
            "probability": 3.057718276977539e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -10.171875,
            "text": "Recently, several serum biomarkers",
            "probability": 2.5570392608642578e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -10.40625,
            "text": "Recently, several serum biomarkers have",
            "probability": 2.0265579223632812e-05
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -11.578125,
            "text": "Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -11.703125,
            "text": "Recently, several serum",
            "probability": 5.543231964111328e-06
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -11.796875,
            "text": "Recently, several serum biomarkers have been",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 9.1171875,
            "end_logit": -11.875,
            "text": "Recently, several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.3984375,
            "end_logit": 0.39453125,
            "text": ", several",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -8.9296875,
            "text": "several serum biomarkers have been proposed",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -9.7265625,
            "text": "several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -10.171875,
            "text": "several serum biomarkers",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -10.40625,
            "text": "several serum biomarkers have",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -11.578125,
            "text": "several serum biomarkers have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -11.703125,
            "text": "several serum",
            "probability": 0.0
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -11.796875,
            "text": "several serum biomarkers have been",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_3": [
        {
            "start_logit": 14.3359375,
            "end_logit": 13.796875,
            "text": "GFAP",
            "probability": 1.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.6640625,
            "text": "GFAP might",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.9140625,
            "text": "GFAP might be the",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -10.9453125,
            "text": "GFAP might be the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.265625,
            "text": "GFAP might be the most appropriate for monitoring NMOSD longitudinally",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.4765625,
            "text": "GFAP might be the most appropriate for monitoring",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.546875,
            "text": "GFAP might be the most appropriate for monitoring NMOSD",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.6953125,
            "text": "GFAP might be the most appropriate",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.875,
            "text": "GFAP might be the most",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -11.9296875,
            "text": "GFAP might be the most appropriate for",
            "probability": 0.0
        },
        {
            "start_logit": 14.3359375,
            "end_logit": -12.1796875,
            "text": "GFAP might be the most appropriate for monitoring NMOSD longitudinally,",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -10.9140625,
            "text": "the",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -10.9453125,
            "text": "the most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -11.265625,
            "text": "the most appropriate for monitoring NMOSD longitudinally",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -10.9453125,
            "text": "most appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -11.4765625,
            "text": "the most appropriate for monitoring",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -11.546875,
            "text": "the most appropriate for monitoring NMOSD",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -11.6953125,
            "text": "the most appropriate",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -10.9453125,
            "text": "appropriate for monitoring NMOSD longitudinally, which warrants future confirming studies.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -11.265625,
            "text": "most appropriate for monitoring NMOSD longitudinally",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_4": [
        {
            "start_logit": 8.4453125,
            "end_logit": 9.8515625,
            "text": "anti-aquaporin-4",
            "probability": 1.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -1.40234375,
            "text": "anti-aquaporin-4 antibody",
            "probability": 1.2993812561035156e-05
        },
        {
            "start_logit": -4.34765625,
            "end_logit": 9.8515625,
            "text": "aquaporin-4",
            "probability": 2.7418136596679688e-06
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -6.625,
            "text": "anti-aquaporin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 9.8515625,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.3671875,
            "text": "anti",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 9.8515625,
            "text": "We prospectively recruited consecutive NMOSD patients with anti-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -8.59375,
            "text": "anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months of follow-up (main period",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 9.8515625,
            "text": "prospectively recruited consecutive NMOSD patients with anti-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -9.25,
            "text": "anti-aquaporin-",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 9.8515625,
            "text": "-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 9.8515625,
            "text": "-4",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 9.8515625,
            "text": "NMOSD patients with anti-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 9.8515625,
            "text": "consecutive NMOSD patients with anti-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.8515625,
            "text": "recruited consecutive NMOSD patients with anti-aquaporin-4",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -9.7890625,
            "text": "anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -10.5703125,
            "text": "anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months of follow-up (main",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -10.578125,
            "text": "anti-aquaporin-4 antibody and",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -11.0234375,
            "text": "anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months of follow-up (main period),",
            "probability": 0.0
        },
        {
            "start_logit": 8.4453125,
            "end_logit": -11.03125,
            "text": "anti-aquaporin-4 antibody and obtained serum samples at enrollment, after 6-12 months of follow-up (main period)",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_5": [
        {
            "start_logit": 13.96875,
            "end_logit": 13.9765625,
            "text": "GFAP",
            "probability": 1.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": 13.9765625,
            "text": "serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.5625,
            "text": "GFAP levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 13.9765625,
            "text": "only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.9765625,
            "text": "attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 13.9765625,
            "text": "new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.9765625,
            "text": "the study, five (8%) patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 13.9765625,
            "text": "five (8%) patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 13.9765625,
            "text": ") patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.9765625,
            "text": "(8%) patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 13.9765625,
            "text": "During the study, five (8%) patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -10.5859375,
            "text": "GFAP levels increased",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 13.9765625,
            "text": "patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.9765625,
            "text": "8%) patients developed new attacks; only serum GFAP",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -11.4375,
            "text": "GFAP levels increased consistently upon these events compared with baseline",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -11.5546875,
            "text": "GFAP levels increased consistently upon these events compared with baseline levels.",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -8.5625,
            "text": "serum GFAP levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.5625,
            "text": "only serum GFAP levels",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -8.5625,
            "text": "levels",
            "probability": 0.0
        },
        {
            "start_logit": -7.80859375,
            "end_logit": -10.5859375,
            "text": "serum GFAP levels increased",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_6": [
        {
            "start_logit": 6.0625,
            "end_logit": 6.4765625,
            "text": "autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.65283203125,
            "end_logit": 6.4765625,
            "text": "Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 0.0012121200561523438
        },
        {
            "start_logit": 6.0625,
            "end_logit": -7.15625,
            "text": "autoantibodies",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -8.375,
            "end_logit": 6.4765625,
            "text": ", reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 6.4765625,
            "text": "(AQP4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.84375,
            "end_logit": 6.4765625,
            "text": "water channel protein aquaporin 4 (AQP4",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.015625,
            "end_logit": 6.4765625,
            "text": "AQP4",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 6.4765625,
            "text": "aquaporin 4 (AQP4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 6.4765625,
            "text": "protein aquaporin 4 (AQP4",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.0625,
            "end_logit": -8.796875,
            "text": "autoantibodies,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.515625,
            "end_logit": 6.4765625,
            "text": "the water channel protein aquaporin 4 (AQP4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 6.4765625,
            "text": "decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.0625,
            "end_logit": -9.5078125,
            "text": "autoantibodies, reactive to the water channel protein aquaporin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.0625,
            "end_logit": -9.59375,
            "text": "autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.125,
            "end_logit": 6.4765625,
            "text": "reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 6.4765625,
            "text": "optic neuritis and myelitis. Two decades of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.0625,
            "end_logit": -9.9453125,
            "text": "autoantibodies, reactive to the water channel protein aquaporin 4 (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4375,
            "end_logit": 6.4765625,
            "text": "of studies have revealed that autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.0625,
            "end_logit": -10.09375,
            "text": "autoantibodies, reactive to the water channel protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.0625,
            "end_logit": -10.328125,
            "text": "autoantibodies, reactive to the water channel protein aquaporin 4 (AQP4) are",
            "probability": 5.960464477539063e-08
        }
    ],
    "641d8fd6690f196b51000041_7": [
        {
            "start_logit": 11.2734375,
            "end_logit": 7.30078125,
            "text": "C3 and C4",
            "probability": 1.0
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -3.10546875,
            "text": "C3 and C4 may",
            "probability": 3.0219554901123047e-05
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -5.66015625,
            "text": "C3 and",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -6.359375,
            "text": "C3",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.1015625,
            "text": "C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -8.5703125,
            "text": "C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB damage",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.12890625,
            "end_logit": 7.30078125,
            "text": "plasma C3 and C4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.2734375,
            "end_logit": -10.1640625,
            "text": "C3 and C4 may become potential biomarkers for distinguishing the two diseases and reflecting the NMOSD BBB damage.",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": 7.30078125,
            "text": "MOGAD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": 7.30078125,
            "text": "C4",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 7.30078125,
            "text": "and C4",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 7.30078125,
            "text": "AD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 7.30078125,
            "text": "NMOSD and MOGAD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 7.30078125,
            "text": "During the acute phase of NMOSD and MOGAD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 7.30078125,
            "text": "the acute phase of NMOSD and MOGAD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 7.30078125,
            "text": ", plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 7.30078125,
            "text": "acute phase of NMOSD and MOGAD, plasma C3 and C4",
            "probability": 0.0
        },
        {
            "start_logit": -5.12890625,
            "end_logit": -3.10546875,
            "text": "plasma C3 and C4 may",
            "probability": 0.0
        },
        {
            "start_logit": -6.63671875,
            "end_logit": -3.10546875,
            "text": "MOGAD, plasma C3 and C4 may",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -3.10546875,
            "text": "C4 may",
            "probability": 0.0
        }
    ],
    "641d8fd6690f196b51000041_8": [
        {
            "start_logit": 3.41796875,
            "end_logit": 0.896484375,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)",
            "probability": 0.6484375
        },
        {
            "start_logit": 2.390625,
            "end_logit": 0.896484375,
            "text": "aquaporin-4 (AQP4)",
            "probability": 0.2325439453125
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -1.28125,
            "text": "The discovery of the pathogenic aquaporin-4",
            "probability": 0.0736083984375
        },
        {
            "start_logit": 2.390625,
            "end_logit": -1.28125,
            "text": "aquaporin-4",
            "probability": 0.0263671875
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -3.0703125,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and",
            "probability": 0.012298583984375
        },
        {
            "start_logit": 2.390625,
            "end_logit": -3.0703125,
            "text": "aquaporin-4 (AQP4)-IgG autoantibody and",
            "probability": 0.00440216064453125
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -5.4140625,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4",
            "probability": 0.0011806488037109375
        },
        {
            "start_logit": 2.390625,
            "end_logit": -5.4140625,
            "text": "aquaporin-4 (AQP4",
            "probability": 0.0004227161407470703
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -8.109375,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy",
            "probability": 7.998943328857422e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -8.734375,
            "text": "The discovery of the pathogenic aquaporin-4 (",
            "probability": 4.285573959350586e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -8.8359375,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody",
            "probability": 3.838539123535156e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -9.0703125,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization",
            "probability": 3.039836883544922e-05
        },
        {
            "start_logit": 2.390625,
            "end_logit": -8.109375,
            "text": "aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy",
            "probability": 2.855062484741211e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -9.1484375,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocytopathy have",
            "probability": 2.8073787689208984e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -9.6015625,
            "text": "The discovery",
            "probability": 1.7881393432617188e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -9.640625,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": 3.41796875,
            "end_logit": -9.6484375,
            "text": "The discovery of the pathogenic aquaporin-4 (AQP4)-IgG autoantibody and characterization of NMOSD as an autoimmune astrocyt",
            "probability": 1.704692840576172e-05
        },
        {
            "start_logit": 2.390625,
            "end_logit": -8.734375,
            "text": "aquaporin-4 (",
            "probability": 1.52587890625e-05
        },
        {
            "start_logit": 2.390625,
            "end_logit": -8.8359375,
            "text": "aquaporin-4 (AQP4)-IgG autoantibody",
            "probability": 1.3828277587890625e-05
        },
        {
            "start_logit": 2.390625,
            "end_logit": -9.0703125,
            "text": "aquaporin-4 (AQP4)-IgG autoantibody and characterization",
            "probability": 1.0907649993896484e-05
        }
    ],
    "641d8fd6690f196b51000041_9": [
        {
            "start_logit": -0.51806640625,
            "end_logit": 3.337890625,
            "text": "neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 0.69287109375
        },
        {
            "start_logit": -1.55078125,
            "end_logit": 3.337890625,
            "text": "serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 0.24658203125
        },
        {
            "start_logit": -3.419921875,
            "end_logit": 3.337890625,
            "text": "glial fibrillary acidic protein (GFAP",
            "probability": 0.03802490234375
        },
        {
            "start_logit": -4.109375,
            "end_logit": 3.337890625,
            "text": ". As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 0.0190887451171875
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 3.337890625,
            "text": "emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 0.0007047653198242188
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -3.595703125,
            "text": "neurofilament light chain and glial fibrillary acidic protein",
            "probability": 0.000675201416015625
        },
        {
            "start_logit": -0.51806640625,
            "end_logit": -3.7265625,
            "text": "neurofilament light chain",
            "probability": 0.0005908012390136719
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -3.595703125,
            "text": "serum neurofilament light chain and glial fibrillary acidic protein",
            "probability": 0.00023984909057617188
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 3.337890625,
            "text": "GFAP",
            "probability": 0.0002200603485107422
        },
        {
            "start_logit": -1.55078125,
            "end_logit": -3.7265625,
            "text": "serum neurofilament light chain",
            "probability": 0.00021159648895263672
        },
        {
            "start_logit": -9.125,
            "end_logit": 3.337890625,
            "text": "immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 0.00012636184692382812
        },
        {
            "start_logit": -9.21875,
            "end_logit": 3.337890625,
            "text": "and glial fibrillary acidic protein (GFAP",
            "probability": 0.0001150369644165039
        },
        {
            "start_logit": -9.84375,
            "end_logit": 3.337890625,
            "text": "light chain and glial fibrillary acidic protein (GFAP",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": -9.84375,
            "end_logit": 3.337890625,
            "text": "As our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": -9.875,
            "end_logit": 3.337890625,
            "text": "including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 5.9664249420166016e-05
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 3.337890625,
            "text": "chain and glial fibrillary acidic protein (GFAP",
            "probability": 4.9114227294921875e-05
        },
        {
            "start_logit": -10.234375,
            "end_logit": 3.337890625,
            "text": "acidic protein (GFAP",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 3.337890625,
            "text": "(GFAP",
            "probability": 3.826618194580078e-05
        },
        {
            "start_logit": -3.419921875,
            "end_logit": -3.595703125,
            "text": "glial fibrillary acidic protein",
            "probability": 3.701448440551758e-05
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 3.337890625,
            "text": "our understanding regarding the immune pathophysiology of NMOSD expands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP",
            "probability": 3.170967102050781e-05
        }
    ],
    "6429d5c557b1c7a315000006_0": [
        {
            "start_logit": 2.1640625,
            "end_logit": 0.505859375,
            "text": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)",
            "probability": 0.97265625
        },
        {
            "start_logit": 3.646484375,
            "end_logit": -4.84765625,
            "text": "myocardial infarction",
            "probability": 0.0202484130859375
        },
        {
            "start_logit": 3.646484375,
            "end_logit": -6.4375,
            "text": "myocardial infarction and cerebrovascular accidents, respectively.",
            "probability": 0.004131317138671875
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -6.23046875,
            "text": "severe acute respiratory syndrome coronavirus 2",
            "probability": 0.0011568069458007812
        },
        {
            "start_logit": 3.646484375,
            "end_logit": -8.71875,
            "text": "myocardial infarction and cerebrovascular accidents",
            "probability": 0.0004222393035888672
        },
        {
            "start_logit": 3.646484375,
            "end_logit": -8.75,
            "text": "myocardial infarction and cerebrovascular",
            "probability": 0.00040912628173828125
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -7.421875,
            "text": "severe acute respiratory syndrome",
            "probability": 0.00034999847412109375
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 0.505859375,
            "text": "acute respiratory syndrome coronavirus 2 (SARS-CoV-2)",
            "probability": 0.0001665353775024414
        },
        {
            "start_logit": -6.5078125,
            "end_logit": 0.505859375,
            "text": "syndrome coronavirus 2 (SARS-CoV-2)",
            "probability": 0.0001665353775024414
        },
        {
            "start_logit": 3.646484375,
            "end_logit": -9.703125,
            "text": "myocardial infarction and cerebrovascular accidents, respectively",
            "probability": 0.00015783309936523438
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -8.6171875,
            "text": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors, platelet",
            "probability": 0.00010591745376586914
        },
        {
            "start_logit": -7.3984375,
            "end_logit": 0.505859375,
            "text": "respiratory syndrome coronavirus 2 (SARS-CoV-2)",
            "probability": 6.842613220214844e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.0703125,
            "text": "severe",
            "probability": 6.729364395141602e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.484375,
            "text": "severe acute respiratory syndrome coronavirus",
            "probability": 4.45246696472168e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.4921875,
            "text": "severe acute respiratory syndrome coronavirus 2 (",
            "probability": 4.416704177856445e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.5078125,
            "text": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such",
            "probability": 4.3451786041259766e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.546875,
            "text": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors, platelet activation",
            "probability": 4.178285598754883e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -9.953125,
            "text": "severe acute",
            "probability": 2.7835369110107422e-05
        },
        {
            "start_logit": 2.1640625,
            "end_logit": -10.125,
            "text": "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections such as alterations in the levels of clotting factors,",
            "probability": 2.3484230041503906e-05
        },
        {
            "start_logit": -8.609375,
            "end_logit": 0.505859375,
            "text": "coronavirus 2 (SARS-CoV-2)",
            "probability": 2.0325183868408203e-05
        }
    ],
    "6429d5c557b1c7a315000006_1": [
        {
            "start_logit": 2.115234375,
            "end_logit": 0.7255859375,
            "text": "prothrombotic state",
            "probability": 0.94140625
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -2.421875,
            "text": "prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial thrombotic events.",
            "probability": 0.04046630859375
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -3.224609375,
            "text": "prothrombotic state is",
            "probability": 0.0181427001953125
        },
        {
            "start_logit": -7.09765625,
            "end_logit": 0.7255859375,
            "text": "A prothrombotic state",
            "probability": 9.40561294555664e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -9.6328125,
            "text": "prothrombotic",
            "probability": 2.9861927032470703e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -9.9140625,
            "text": "prothrombotic state is reported with severe COVID-19 infection,",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -9.984375,
            "text": "prothrombotic state is reported",
            "probability": 2.1159648895263672e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -10.3203125,
            "text": "prothrombotic state is reported with severe COVID-19 infection, which can manifest in venous and arterial",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -10.6171875,
            "text": "prothrombotic state is reported with severe COVID-19 infection, which",
            "probability": 1.1146068572998047e-05
        },
        {
            "start_logit": -6.08984375,
            "end_logit": -2.421875,
            "text": "venous and arterial thrombotic events.",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 0.7255859375,
            "text": "hrombotic state",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -10.703125,
            "text": "prothrombotic state is reported with severe",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -10.78125,
            "text": "prothromb",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -10.8359375,
            "text": "prothrombotic state is reported with severe COVID-19 infection",
            "probability": 9.000301361083984e-06
        },
        {
            "start_logit": -9.46875,
            "end_logit": 0.7255859375,
            "text": "state",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -11.1171875,
            "text": "prothr",
            "probability": 6.794929504394531e-06
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -11.25,
            "text": "prothrombotic state is reported with severe COVID-19 infection, which can",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 0.7255859375,
            "text": "ombotic state",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -11.3125,
            "text": "prothrombotic state is reported with severe COVID-19 infection, which can manifest",
            "probability": 5.602836608886719e-06
        },
        {
            "start_logit": 2.115234375,
            "end_logit": -11.4609375,
            "text": "prothrombotic state is reported with",
            "probability": 4.76837158203125e-06
        }
    ],
    "6429d5c557b1c7a315000006_2": [
        {
            "start_logit": 14.5234375,
            "end_logit": 10.953125,
            "text": "deep venous thrombosis",
            "probability": 1.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": 1.20703125,
            "text": "deep venous thrombosis reported in 16.1% and pulmonary embolism",
            "probability": 5.918741226196289e-05
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -3.52734375,
            "text": "deep venous thrombosis reported in 16.1% and pulmonary",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -5.671875,
            "text": "deep",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.01171875,
            "text": "deep venous",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.15625,
            "text": "deep venous thrombosis reported",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.53515625,
            "text": "deep venous thrombosis reported in 16.1% and",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 10.953125,
            "text": "thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.6015625,
            "text": "deep venous thrombosis reported in 16.1% and pulmonary embolism in 12.6% of patients, despite anticoagulant thromboprophylaxis",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 10.953125,
            "text": "venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.8671875,
            "text": "deep venous thrombosis reported in 16.1% and pulmonary embolism in 12",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -10.8828125,
            "text": "deep venous thrombosis reported in 16.1%",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 10.953125,
            "text": "thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 10.953125,
            "text": "ICU-managed patients, with deep venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 10.953125,
            "text": "28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 10.953125,
            "text": "2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 10.953125,
            "text": "In 28 studies including 2928 patients, thrombotic complications occurred in 34% of ICU-managed patients, with deep venous thrombosis",
            "probability": 0.0
        },
        {
            "start_logit": -1.59765625,
            "end_logit": 1.20703125,
            "text": "pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -5.26953125,
            "end_logit": 1.20703125,
            "text": "thrombosis reported in 16.1% and pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 1.20703125,
            "text": "embolism",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_3": [
        {
            "start_logit": -5.734375,
            "end_logit": -2.451171875,
            "text": "high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.7451171875
        },
        {
            "start_logit": -8.03125,
            "end_logit": -2.451171875,
            "text": "thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.074951171875
        },
        {
            "start_logit": -8.6171875,
            "end_logit": -2.451171875,
            "text": "thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.041717529296875
        },
        {
            "start_logit": -5.734375,
            "end_logit": -5.484375,
            "text": "high incidence of thrombotic complications in patients with COVID-19 on the ICU",
            "probability": 0.03594970703125
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -2.451171875,
            "text": "ICU.",
            "probability": 0.031494140625
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -2.451171875,
            "text": "is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.01038360595703125
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -2.451171875,
            "text": "COVID-19 on the ICU.",
            "probability": 0.00991058349609375
        },
        {
            "start_logit": -5.734375,
            "end_logit": -6.984375,
            "text": "high",
            "probability": 0.008026123046875
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -2.451171875,
            "text": "incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.00582122802734375
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -2.451171875,
            "text": "a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.00475311279296875
        },
        {
            "start_logit": -10.796875,
            "end_logit": -2.451171875,
            "text": "very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.0047149658203125
        },
        {
            "start_logit": -8.03125,
            "end_logit": -5.484375,
            "text": "thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU",
            "probability": 0.0036163330078125
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -2.451171875,
            "text": "complications in patients with COVID-19 on the ICU.",
            "probability": 0.0035343170166015625
        },
        {
            "start_logit": -11.140625,
            "end_logit": -2.451171875,
            "text": "ID-19 on the ICU.",
            "probability": 0.003345489501953125
        },
        {
            "start_logit": -11.25,
            "end_logit": -2.451171875,
            "text": "there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.0030002593994140625
        },
        {
            "start_logit": -11.265625,
            "end_logit": -2.451171875,
            "text": "on the ICU.",
            "probability": 0.0029506683349609375
        },
        {
            "start_logit": -11.296875,
            "end_logit": -2.451171875,
            "text": "Despite thromboprophylaxis, there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.00286102294921875
        },
        {
            "start_logit": -11.3828125,
            "end_logit": -2.451171875,
            "text": "patients with COVID-19 on the ICU.",
            "probability": 0.0026264190673828125
        },
        {
            "start_logit": -11.4296875,
            "end_logit": -2.451171875,
            "text": "of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.0025043487548828125
        },
        {
            "start_logit": -11.4609375,
            "end_logit": -2.451171875,
            "text": ", there is a very high incidence of thrombotic complications in patients with COVID-19 on the ICU.",
            "probability": 0.0024280548095703125
        }
    ],
    "6429d5c557b1c7a315000006_4": [
        {
            "start_logit": 4.72265625,
            "end_logit": 9.1953125,
            "text": "stroke",
            "probability": 0.9990234375
        },
        {
            "start_logit": -3.470703125,
            "end_logit": 9.1953125,
            "text": "venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 0.00027561187744140625
        },
        {
            "start_logit": -3.80859375,
            "end_logit": 9.1953125,
            "text": "myocardial injury/infarction and stroke",
            "probability": 0.00019693374633789062
        },
        {
            "start_logit": -7.296875,
            "end_logit": 9.1953125,
            "text": "injury/infarction and stroke",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 9.1953125,
            "text": "including venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -8.40625,
            "end_logit": 9.1953125,
            "text": "infarction and stroke",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -8.546875,
            "end_logit": 9.1953125,
            "text": "and stroke",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -8.578125,
            "end_logit": 9.1953125,
            "text": "macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -8.921875,
            "end_logit": 9.1953125,
            "text": ", myocardial injury/infarction and stroke",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 9.1953125,
            "text": "vascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -9.609375,
            "end_logit": 9.1953125,
            "text": "thromboembolism, myocardial injury/infarction and stroke",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.65625,
            "end_logit": 9.1953125,
            "text": "hospitalized due to severe COVID-19 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.765625,
            "end_logit": 9.1953125,
            "text": "of patients hospitalized due to severe COVID-19 develops macrovascular thrombotic complications, including venous thromboembolism, myocardial injury/infarction and stroke",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.72265625,
            "end_logit": -10.421875,
            "text": "stroke.",
            "probability": 0.0
        },
        {
            "start_logit": -0.44677734375,
            "end_logit": -7.7265625,
            "text": "Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism",
            "probability": 0.0
        },
        {
            "start_logit": -0.44677734375,
            "end_logit": -9.078125,
            "text": "Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism.",
            "probability": 0.0
        },
        {
            "start_logit": -3.470703125,
            "end_logit": -7.0,
            "text": "venous thromboembolism",
            "probability": 0.0
        },
        {
            "start_logit": -0.44677734375,
            "end_logit": -10.6328125,
            "text": "Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk",
            "probability": 0.0
        },
        {
            "start_logit": -0.44677734375,
            "end_logit": -10.984375,
            "text": "Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism. One",
            "probability": 0.0
        },
        {
            "start_logit": -0.44677734375,
            "end_logit": -11.4296875,
            "text": "Emerging evidence points to an association between severe clinical presentation of COVID-19 and increased risk of thromboembolism. One-third",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_5": [
        {
            "start_logit": 11.859375,
            "end_logit": 4.51171875,
            "text": "venous thromboembolism",
            "probability": 0.9580078125
        },
        {
            "start_logit": 11.859375,
            "end_logit": 0.99853515625,
            "text": "venous thromboembolism (VTE) and",
            "probability": 0.028472900390625
        },
        {
            "start_logit": 11.859375,
            "end_logit": 0.2442626953125,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation",
            "probability": 0.01334381103515625
        },
        {
            "start_logit": 11.859375,
            "end_logit": -3.609375,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC",
            "probability": 0.0002837181091308594
        },
        {
            "start_logit": 7.640625,
            "end_logit": 0.2442626953125,
            "text": "disseminated intravascular coagulation",
            "probability": 0.00019800662994384766
        },
        {
            "start_logit": 11.859375,
            "end_logit": -4.29296875,
            "text": "venous thromboembolism (VTE)",
            "probability": 0.00014257431030273438
        },
        {
            "start_logit": 11.859375,
            "end_logit": -7.28515625,
            "text": "venous thromboembolism (VTE",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": 11.859375,
            "end_logit": -7.57421875,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation (",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": 7.640625,
            "end_logit": -3.609375,
            "text": "disseminated intravascular coagulation (DIC",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": 11.859375,
            "end_logit": -7.8828125,
            "text": "venous",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 11.859375,
            "end_logit": -9.4453125,
            "text": "venous thromboembolism (",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 11.859375,
            "end_logit": -9.4921875,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 11.859375,
            "end_logit": -9.6953125,
            "text": "venous thromboembolism (VTE) and disseminated",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 11.859375,
            "end_logit": -10.3359375,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 11.859375,
            "end_logit": -10.9921875,
            "text": "venous thromboembolism (VTE) and disseminated intravascular",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.859375,
            "end_logit": -11.296875,
            "text": "venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.640625,
            "end_logit": -7.57421875,
            "text": "disseminated intravascular coagulation (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.4921875,
            "text": "disseminated intravascular coagulation (DIC) rates",
            "probability": 0.0
        },
        {
            "start_logit": 7.640625,
            "end_logit": -9.6953125,
            "text": "disseminated",
            "probability": 0.0
        },
        {
            "start_logit": -6.58984375,
            "end_logit": 4.51171875,
            "text": "thromboembolism",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_6": [
        {
            "start_logit": 14.8828125,
            "end_logit": 12.8359375,
            "text": "VTE",
            "probability": 1.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.1953125,
            "text": "VTE rate",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.8203125,
            "text": "VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.84375,
            "text": "VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 12.8359375,
            "text": "The radiographically confirmed VTE",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -10.03125,
            "text": "5% (95% CI, 6.8-12.8). The overall and major bleeding",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -9.7421875,
            "text": "VTE",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -11.8203125,
            "text": "5",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -11.8359375,
            "text": "5%",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -10.03125,
            "text": "bleeding",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -11.8984375,
            "text": "5% (95% CI, 6.8-12.8). The overall and major bleeding rates",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -11.9140625,
            "text": "5% (95% CI, 6.8-12",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -11.984375,
            "text": "5% (95% CI, 6.8-12.8). The overall",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -12.0546875,
            "text": "5% (95% CI, 6.8-12.8). The overall and",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -10.03125,
            "text": "major bleeding",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.7421875,
            "text": ".3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -9.7421875,
            "text": "3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -10.03125,
            "text": "thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -11.8359375,
            "text": "VTE and major bleeding rates",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.7421875,
            "text": "critically ill, radiographically confirmed VTE",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_7": [
        {
            "start_logit": 14.25,
            "end_logit": 6.05859375,
            "text": "pulmonary embolisms",
            "probability": 0.9892578125
        },
        {
            "start_logit": 14.25,
            "end_logit": 1.560546875,
            "text": "pulmonary embolism",
            "probability": 0.01099395751953125
        },
        {
            "start_logit": 14.25,
            "end_logit": -5.80078125,
            "text": "pulmonary",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 14.25,
            "end_logit": -10.2265625,
            "text": "pulmonary embolisms (16.7%).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.25,
            "end_logit": -11.296875,
            "text": "pulmonary embolisms (16",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -11.3359375,
            "text": "pulmonary embolisms (16.7%",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -11.6640625,
            "text": "pulmonary embolisms (16.7",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -11.765625,
            "text": "pulmonary embolisms (",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -11.765625,
            "text": "pulmonary embolisms (16.",
            "probability": 0.0
        },
        {
            "start_logit": -3.75,
            "end_logit": 6.05859375,
            "text": "embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 6.05859375,
            "text": "s",
            "probability": 0.0
        },
        {
            "start_logit": -7.92578125,
            "end_logit": 6.05859375,
            "text": "four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -3.75,
            "end_logit": 1.560546875,
            "text": "embolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 6.05859375,
            "text": "Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 6.05859375,
            "text": "thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 6.05859375,
            "text": "-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 6.05859375,
            "text": "clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 6.05859375,
            "text": "complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 6.05859375,
            "text": "relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 6.05859375,
            "text": "diagnosed in 150 patients, mainly pulmonary embolisms",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_8": [
        {
            "start_logit": 16.21875,
            "end_logit": 15.546875,
            "text": "disseminated intravascular coagulation",
            "probability": 1.0
        },
        {
            "start_logit": 16.21875,
            "end_logit": -3.14453125,
            "text": "disseminated",
            "probability": 0.0
        },
        {
            "start_logit": -4.9765625,
            "end_logit": 15.546875,
            "text": "coagulation",
            "probability": 0.0
        },
        {
            "start_logit": 16.21875,
            "end_logit": -6.3203125,
            "text": "disseminated intravascular coagulation.",
            "probability": 0.0
        },
        {
            "start_logit": 16.21875,
            "end_logit": -6.4609375,
            "text": "disseminated intravascular",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": 15.546875,
            "text": "No patient developed disseminated intravascular coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 15.546875,
            "text": "intravascular coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 15.546875,
            "text": "developed disseminated intravascular coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 15.546875,
            "text": "patient developed disseminated intravascular coagulation",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -3.14453125,
            "text": "No patient developed disseminated",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -3.14453125,
            "text": "developed disseminated",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -3.14453125,
            "text": "patient developed disseminated",
            "probability": 0.0
        },
        {
            "start_logit": -4.9765625,
            "end_logit": -6.3203125,
            "text": "coagulation.",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -6.3203125,
            "text": "No patient developed disseminated intravascular coagulation.",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -6.4609375,
            "text": "No patient developed disseminated intravascular",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -6.46875,
            "text": "No patient developed",
            "probability": 0.0
        },
        {
            "start_logit": -5.91015625,
            "end_logit": -7.13671875,
            "text": "No",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -6.3203125,
            "text": "intravascular coagulation.",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -6.4609375,
            "text": "intravascular",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": -6.3203125,
            "text": "developed disseminated intravascular coagulation.",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_9": [
        {
            "start_logit": 0.5537109375,
            "end_logit": -0.63330078125,
            "text": "ARDS",
            "probability": 0.9921875
        },
        {
            "start_logit": -5.18359375,
            "end_logit": -0.63330078125,
            "text": "high number of patients with ARDS",
            "probability": 0.0031948089599609375
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -6.4765625,
            "text": "ARDS secondary to COVID-19 developed life-threatening thrombotic complications.",
            "probability": 0.0028743743896484375
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -7.8828125,
            "text": "ARDS secondary to COVID-19 developed",
            "probability": 0.0007042884826660156
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -9.2578125,
            "text": "ARDS secondary to COVID-19 developed life-threatening thrombotic complications",
            "probability": 0.0001780986785888672
        },
        {
            "start_logit": -8.8828125,
            "end_logit": -0.63330078125,
            "text": "anticoagulation, a high number of patients with ARDS",
            "probability": 7.909536361694336e-05
        },
        {
            "start_logit": -9.1171875,
            "end_logit": -0.63330078125,
            "text": "a high number of patients with ARDS",
            "probability": 6.252527236938477e-05
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -10.4296875,
            "text": "ARDS secondary to COVID-19 developed life-",
            "probability": 5.519390106201172e-05
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -10.59375,
            "text": "ARDS secondary to COVID-19 developed life",
            "probability": 4.684925079345703e-05
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -11.140625,
            "text": "ARDS secondary to COVID-19 developed life-threatening",
            "probability": 2.7060508728027344e-05
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -11.171875,
            "text": "ARDS secondary",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 0.5537109375,
            "end_logit": -11.21875,
            "text": "ARDS secondary to COVID-19 developed life-threatening thrombotic",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -10.1875,
            "end_logit": -0.63330078125,
            "text": ", a high number of patients with ARDS",
            "probability": 2.1457672119140625e-05
        },
        {
            "start_logit": -10.265625,
            "end_logit": -0.63330078125,
            "text": "Despite anticoagulation, a high number of patients with ARDS",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": -5.18359375,
            "end_logit": -5.953125,
            "text": "high",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": -10.90625,
            "end_logit": -0.63330078125,
            "text": "patients with ARDS",
            "probability": 1.049041748046875e-05
        },
        {
            "start_logit": -5.18359375,
            "end_logit": -6.4765625,
            "text": "high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications.",
            "probability": 9.298324584960938e-06
        },
        {
            "start_logit": -11.140625,
            "end_logit": -0.63330078125,
            "text": "of patients with ARDS",
            "probability": 8.285045623779297e-06
        },
        {
            "start_logit": -11.4296875,
            "end_logit": -0.63330078125,
            "text": "number of patients with ARDS",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -11.4453125,
            "end_logit": -0.63330078125,
            "text": "with ARDS",
            "probability": 6.079673767089844e-06
        }
    ],
    "6429d5c557b1c7a315000006_10": [
        {
            "start_logit": -4.0390625,
            "end_logit": -1.232421875,
            "text": "bleeds",
            "probability": 0.79833984375
        },
        {
            "start_logit": -5.546875,
            "end_logit": -1.232421875,
            "text": "major life-threatening bleeds",
            "probability": 0.1767578125
        },
        {
            "start_logit": -8.9921875,
            "end_logit": -1.232421875,
            "text": "life-threatening bleeds",
            "probability": 0.005634307861328125
        },
        {
            "start_logit": -9.3359375,
            "end_logit": -1.232421875,
            "text": "mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.003997802734375
        },
        {
            "start_logit": -9.484375,
            "end_logit": -1.232421875,
            "text": "COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0034465789794921875
        },
        {
            "start_logit": -9.6875,
            "end_logit": -1.232421875,
            "text": "threatening bleeds",
            "probability": 0.002811431884765625
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -1.232421875,
            "text": "thrombotic events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0014476776123046875
        },
        {
            "start_logit": -10.421875,
            "end_logit": -1.232421875,
            "text": "risk of serious thrombotic events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0013484954833984375
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -1.232421875,
            "text": "events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0012979507446289062
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -1.232421875,
            "text": "increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0011997222900390625
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -1.232421875,
            "text": "eds",
            "probability": 0.001110076904296875
        },
        {
            "start_logit": -10.671875,
            "end_logit": -1.232421875,
            "text": "increased risk of serious thrombotic events and hence increased mortality. On the other side, COVID-19 patients are also showing major life-threatening bleeds",
            "probability": 0.0010499954223632812
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -7.99609375,
            "text": "ble",
            "probability": 0.000926971435546875
        },
        {
            "start_logit": -5.546875,
            "end_logit": -7.99609375,
            "text": "major life-threatening ble",
            "probability": 0.00020360946655273438
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -10.2265625,
            "text": "bleeds, especially when systemic anticoagulation",
            "probability": 9.924173355102539e-05
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -10.2421875,
            "text": "bleeds, especially when systemic anticoagulation is used.",
            "probability": 9.769201278686523e-05
        },
        {
            "start_logit": -4.0390625,
            "end_logit": -11.1328125,
            "text": "bleeds, especially when systemic anticoagulation is",
            "probability": 4.011392593383789e-05
        },
        {
            "start_logit": -5.546875,
            "end_logit": -10.2265625,
            "text": "major life-threatening bleeds, especially when systemic anticoagulation",
            "probability": 2.199411392211914e-05
        },
        {
            "start_logit": -5.546875,
            "end_logit": -10.2421875,
            "text": "major life-threatening bleeds, especially when systemic anticoagulation is used.",
            "probability": 2.1636486053466797e-05
        },
        {
            "start_logit": -5.546875,
            "end_logit": -10.9375,
            "text": "major life",
            "probability": 1.0788440704345703e-05
        }
    ],
    "6429d5c557b1c7a315000006_11": [
        {
            "start_logit": 10.0078125,
            "end_logit": -2.197265625,
            "text": "Major bleeding",
            "probability": 0.98291015625
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -6.90625,
            "text": "Major bleeding occurred in six",
            "probability": 0.00884246826171875
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -7.22265625,
            "text": "Major bleeding occurred in six of the 25 studied patients.",
            "probability": 0.006443023681640625
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -9.3359375,
            "text": "Major",
            "probability": 0.0007781982421875
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -10.0234375,
            "text": "Major bleeding occurred",
            "probability": 0.0003914833068847656
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -10.15625,
            "text": "Major bleeding occurred in",
            "probability": 0.0003428459167480469
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -10.421875,
            "text": "Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation",
            "probability": 0.00026297569274902344
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -10.7421875,
            "text": "Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed",
            "probability": 0.00019085407257080078
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -11.1796875,
            "text": "Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the ble",
            "probability": 0.0001232624053955078
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -11.3125,
            "text": "Major bleeding occurred in six of the 25",
            "probability": 0.00010788440704345703
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -11.65625,
            "text": "Major bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed,",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -11.71875,
            "text": "Major bleeding occurred in six of",
            "probability": 7.18832015991211e-05
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -2.197265625,
            "text": "bleeding",
            "probability": 4.750490188598633e-05
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -6.90625,
            "text": "bleeding occurred in six",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -7.22265625,
            "text": "bleeding occurred in six of the 25 studied patients.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -10.0234375,
            "text": "bleeding occurred",
            "probability": 0.0
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -10.15625,
            "text": "bleeding occurred in",
            "probability": 0.0
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -10.421875,
            "text": "bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation",
            "probability": 0.0
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -10.7421875,
            "text": "bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the bleed",
            "probability": 0.0
        },
        {
            "start_logit": 0.071044921875,
            "end_logit": -11.1796875,
            "text": "bleeding occurred in six of the 25 studied patients. Four patients were on therapeutic anticoagulation at the onset of the ble",
            "probability": 0.0
        }
    ],
    "6429d5c557b1c7a315000006_12": [
        {
            "start_logit": 15.3359375,
            "end_logit": 13.1640625,
            "text": "intracerebral hemorrhage",
            "probability": 1.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -3.017578125,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -4.58984375,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -4.921875,
            "text": "intracerebral",
            "probability": 0.0
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 13.1640625,
            "text": "hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -9.6953125,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19.",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -10.25,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -10.8203125,
            "text": "intracerebral hemorrhage are higher",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -10.8828125,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -11.3828125,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -11.53125,
            "text": "intracerebral hemorrhage are",
            "probability": 0.0
        },
        {
            "start_logit": 15.3359375,
            "end_logit": -11.640625,
            "text": "intracerebral hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage and",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 13.1640625,
            "text": "rates of intracerebral hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 13.1640625,
            "text": "that rates of intracerebral hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 13.1640625,
            "text": "Our analysis does not suggest that rates of intracerebral hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.1640625,
            "text": "of intracerebral hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -3.017578125,
            "text": "intracerebral hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -2.8671875,
            "end_logit": -4.58984375,
            "text": "intracerebral",
            "probability": 0.0
        },
        {
            "start_logit": -5.578125,
            "end_logit": -3.017578125,
            "text": "hemorrhage",
            "probability": 0.0
        },
        {
            "start_logit": -5.81640625,
            "end_logit": -3.017578125,
            "text": "hemorrhage are higher in patients with COVID-19. The higher mortality in patients with intracerebral hemorrhage",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_0": [
        {
            "start_logit": 16.0,
            "end_logit": 15.84375,
            "text": "lysine and arginine",
            "probability": 1.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -2.3671875,
            "text": "lysine",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": 15.84375,
            "text": "Histone lysine and arginine",
            "probability": 0.0
        },
        {
            "start_logit": -4.41796875,
            "end_logit": 15.84375,
            "text": "arginine",
            "probability": 0.0
        },
        {
            "start_logit": -7.1953125,
            "end_logit": 15.84375,
            "text": "and arginine",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -7.76171875,
            "text": "lysine and",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -9.2890625,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -9.5390625,
            "text": "lysine and arginine residues",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -10.078125,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -10.7265625,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -10.984375,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -11.1875,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -11.1875,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumo",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -11.2265625,
            "text": "lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation",
            "probability": 0.0
        },
        {
            "start_logit": 16.0,
            "end_logit": -11.28125,
            "text": "lysine and arginine residues are",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": -2.3671875,
            "text": "Histone lysine",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": -7.73046875,
            "text": "Histone",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": -7.76171875,
            "text": "Histone lysine and",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": -9.2890625,
            "text": "Histone lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation",
            "probability": 0.0
        },
        {
            "start_logit": -3.83984375,
            "end_logit": -9.5390625,
            "text": "Histone lysine and arginine residues",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_1": [
        {
            "start_logit": 11.65625,
            "end_logit": 11.4765625,
            "text": "Histone methylation",
            "probability": 1.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -4.8984375,
            "text": "Histone methylation represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.65625,
            "end_logit": -7.46875,
            "text": "Histone methylation represents one",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 11.4765625,
            "text": "methylation",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -7.87890625,
            "text": "Histone",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -10.265625,
            "text": "Histone methylation represents one of the most critical epigenetic events in DNA function regulation in",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -11.1171875,
            "text": "Histone methylation represents one of the most critical epigenetic events in DNA function",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -11.1484375,
            "text": "Histone methylation represents one of the most critical epigenetic events in DNA function regulation",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -11.1796875,
            "text": "Histone methylation represents",
            "probability": 0.0
        },
        {
            "start_logit": 11.65625,
            "end_logit": -11.34375,
            "text": "Histone methylation represents one of the most critical epigenetic",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -4.8984375,
            "text": "methylation represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -4.8984375,
            "text": "one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -4.8984375,
            "text": "DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -4.8984375,
            "text": "epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": -7.46875,
            "text": "methylation represents one",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -4.8984375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -4.8984375,
            "text": "represents one of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -4.8984375,
            "text": "of the most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -4.8984375,
            "text": "most critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": -4.8984375,
            "text": "critical epigenetic events in DNA function regulation in eukaryotic organisms.",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_2": [
        {
            "start_logit": 11.9453125,
            "end_logit": 13.15625,
            "text": "acetylation",
            "probability": 1.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -4.93359375,
            "text": "acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 13.15625,
            "text": "notably acetylation",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 13.15625,
            "text": "Studies into posttranslational modifications of histones, notably acetylation",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.15625,
            "text": "posttranslational modifications of histones, notably acetylation",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.15625,
            "text": "histones, notably acetylation",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -9.3203125,
            "text": "acetylation,",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.34375,
            "text": "acetylation, have yielded important insights into the dynamic nature of chromatin structure",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.9453125,
            "text": "acetylation, have",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -10.984375,
            "text": "acetylation, have yielded important insights into the dynamic nature of chromatin",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -11.15625,
            "text": "acetylation, have yielded important insights into the dynamic nature of",
            "probability": 0.0
        },
        {
            "start_logit": 11.9453125,
            "end_logit": -11.2890625,
            "text": "acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -7.19140625,
            "end_logit": -4.93359375,
            "text": "important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -4.93359375,
            "text": "notably acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": -4.93359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -4.93359375,
            "text": "Studies into posttranslational modifications of histones, notably acetylation, have yielded important insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6171875,
            "end_logit": -4.93359375,
            "text": "chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": -4.93359375,
            "text": "dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": -4.93359375,
            "text": "insights into the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -4.93359375,
            "text": "the dynamic nature of chromatin structure and its fundamental role in gene expression.",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_3": [
        {
            "start_logit": 15.2109375,
            "end_logit": 15.546875,
            "text": "lysine 4",
            "probability": 1.0
        },
        {
            "start_logit": -2.650390625,
            "end_logit": 15.546875,
            "text": "H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -3.48828125,
            "text": "lysine 4 is a highly conserved site of methylation",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -4.6953125,
            "text": "lysine",
            "probability": 0.0
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 15.546875,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": -5.65625,
            "end_logit": 15.546875,
            "text": "that lysine 4",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -5.71875,
            "text": "lysine 4 is a highly conserved site of methylation, which to date,",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -5.80078125,
            "text": "lysine 4 is",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 15.546875,
            "text": "Microsequence analyses of H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -7.71484375,
            "text": "lysine 4 is a highly conserved site of methylation, which to date, is",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -8.3125,
            "text": "lysine 4 is a highly conserved site of methylation, which to date, is the major site detected in Tetrahymena and yeast.",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -8.328125,
            "text": "lysine 4 is a highly conserved site of methylation, which to date, is the major site",
            "probability": 0.0
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 15.546875,
            "text": "of H3 from Tetrahymena, yeast, and HeLa cells indicate that lysine 4",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -8.6328125,
            "text": "lysine 4 is a highly conserved site of methylation, which to date, is the",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -8.8046875,
            "text": "lysine 4 is a highly conserved site of methylation, which to date",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -9.0546875,
            "text": "lysine 4 is a highly conserved site of methylation, which",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -9.1015625,
            "text": "lysine 4 is a highly conserved site of methylation, which to date, is the major",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -9.1953125,
            "text": "lysine 4 is a highly conserved site",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -9.234375,
            "text": "lysine 4 is a highly conserved site of methylation,",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -9.3046875,
            "text": "lysine 4 is a highly conserved site of",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_4": [
        {
            "start_logit": 11.7265625,
            "end_logit": 11.3359375,
            "text": "Methylation of histone H3 at lysine 4",
            "probability": 1.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": 2.8203125,
            "text": "Methylation of histone H3",
            "probability": 0.0002002716064453125
        },
        {
            "start_logit": -1.896484375,
            "end_logit": 11.3359375,
            "text": "histone H3 at lysine 4",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -2.205078125,
            "end_logit": 11.3359375,
            "text": "lysine 4",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -3.751953125,
            "text": "Methylation of histone H3 at lysine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -3.779296875,
            "text": "Methylation of histone H3 at",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.94921875,
            "end_logit": 11.3359375,
            "text": "at lysine 4",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -4.66015625,
            "text": "Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.58984375,
            "end_logit": 11.3359375,
            "text": "H3 at lysine 4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -5.1875,
            "text": "Methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.52734375,
            "end_logit": 11.3359375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 11.3359375,
            "text": "of histone H3 at lysine 4",
            "probability": 0.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -9.1015625,
            "text": "Methylation of histone",
            "probability": 0.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -9.2421875,
            "text": "Methylation of",
            "probability": 0.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -10.4765625,
            "text": "Methylation of histone H3 at lysine 4 is",
            "probability": 0.0
        },
        {
            "start_logit": -1.896484375,
            "end_logit": 2.8203125,
            "text": "histone H3",
            "probability": 0.0
        },
        {
            "start_logit": 11.7265625,
            "end_logit": -10.8125,
            "text": "Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in",
            "probability": 0.0
        },
        {
            "start_logit": -4.58984375,
            "end_logit": 2.8203125,
            "text": "H3",
            "probability": 0.0
        },
        {
            "start_logit": -7.94140625,
            "end_logit": 2.8203125,
            "text": "of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -1.896484375,
            "end_logit": -3.751953125,
            "text": "histone H3 at lysine",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_5": [
        {
            "start_logit": -6.37109375,
            "end_logit": 0.4580078125,
            "text": "acetyltransferase/ADA (SAGA/ADA",
            "probability": 0.416015625
        },
        {
            "start_logit": -5.27734375,
            "end_logit": -1.7666015625,
            "text": "acetylated during the bacterial fungal interaction, which, furthermore, was associated with the activation of the otherwise silent orsellinic acid gene cluster.",
            "probability": 0.134521484375
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -4.60546875,
            "text": "H3",
            "probability": 0.1239013671875
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 0.4580078125,
            "text": "SAGA/ADA",
            "probability": 0.11187744140625
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 0.4580078125,
            "text": "Streptomyces rapamycinicus, is able to reprogram the histone-modifying Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA",
            "probability": 0.0565185546875
        },
        {
            "start_logit": -8.40625,
            "end_logit": 0.4580078125,
            "text": ", Streptomyces rapamycinicus, is able to reprogram the histone-modifying Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA",
            "probability": 0.0543212890625
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 0.4580078125,
            "text": "(SAGA/ADA",
            "probability": 0.028533935546875
        },
        {
            "start_logit": -9.40625,
            "end_logit": 0.4580078125,
            "text": "Spt-Ada-Gcn5-acetyltransferase/ADA (SAGA/ADA",
            "probability": 0.0200653076171875
        },
        {
            "start_logit": -9.609375,
            "end_logit": 0.4580078125,
            "text": "ADA",
            "probability": 0.016387939453125
        },
        {
            "start_logit": -4.85546875,
            "end_logit": -4.60546875,
            "text": "histone H3",
            "probability": 0.01198577880859375
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -7.73828125,
            "text": "H3 amino acids lysine 9 and lysine 14 at distinct secondary metabolism genes were specifically acetylated",
            "probability": 0.005401611328125
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -7.921875,
            "text": "H3 amino acids lysine",
            "probability": 0.004512786865234375
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -8.1484375,
            "text": "H3 amino acids lysine 9 and lysine",
            "probability": 0.0035991668701171875
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -1.7666015625,
            "text": "activation of the otherwise silent orsellinic acid gene cluster.",
            "probability": 0.0030307769775390625
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -4.60546875,
            "text": "acetyltransferase/ADA (SAGA/ADA) complex of the model fungus Aspergillus nidulans. Consequently, the histone H3",
            "probability": 0.00263214111328125
        },
        {
            "start_logit": -9.515625,
            "end_logit": -1.7666015625,
            "text": "orsellinic acid gene cluster.",
            "probability": 0.0019407272338867188
        },
        {
            "start_logit": -6.70703125,
            "end_logit": -4.60546875,
            "text": "the histone H3",
            "probability": 0.0018815994262695312
        },
        {
            "start_logit": -2.517578125,
            "end_logit": -9.1015625,
            "text": "H3 amino acids",
            "probability": 0.0013875961303710938
        },
        {
            "start_logit": -6.37109375,
            "end_logit": -5.4453125,
            "text": "acetyltransferase",
            "probability": 0.0011415481567382812
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -4.60546875,
            "text": "SAGA/ADA) complex of the model fungus Aspergillus nidulans. Consequently, the histone H3",
            "probability": 0.0007085800170898438
        }
    ],
    "6429b41757b1c7a315000004_6": [
        {
            "start_logit": 2.025390625,
            "end_logit": 8.7578125,
            "text": "methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine",
            "probability": 0.990234375
        },
        {
            "start_logit": -2.61328125,
            "end_logit": 8.7578125,
            "text": "lysine and arginine",
            "probability": 0.0095977783203125
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 8.7578125,
            "text": "arginine",
            "probability": 0.0002753734588623047
        },
        {
            "start_logit": -1.1240234375,
            "end_logit": 2.75390625,
            "text": "heterochromatic repression",
            "probability": 0.00010538101196289062
        },
        {
            "start_logit": -2.61328125,
            "end_logit": 2.75390625,
            "text": "lysine and arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 2.3663043975830078e-05
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -1.9453125,
            "text": "methylation",
            "probability": 2.2232532501220703e-05
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 8.7578125,
            "text": "and arginine",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": -9.796875,
            "end_logit": 8.7578125,
            "text": "histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine",
            "probability": 7.271766662597656e-06
        },
        {
            "start_logit": -5.27734375,
            "end_logit": 2.75390625,
            "text": "methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -5.7265625,
            "end_logit": 2.75390625,
            "text": "lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 2.75390625,
            "text": "repression",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -5.24609375,
            "text": "methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine and arginine methyltransferase",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 2.75390625,
            "text": "arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 2.025390625,
            "end_logit": -6.07421875,
            "text": "methylation of histones has come to be recognised as a major player in the regulation of gene activity. This notion follows the discovery of lysine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.41015625,
            "end_logit": 2.75390625,
            "text": "been implicated in heterochromatic repression",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 2.75390625,
            "text": "the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 2.75390625,
            "text": "and arginine methyltransferases and proteins that recognise the methyl-lysine 'mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 2.75390625,
            "text": "mark' on histones. Methylated histones have been implicated in heterochromatic repression",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 2.75390625,
            "text": "Methylated histones have been implicated in heterochromatic repression",
            "probability": 0.0
        },
        {
            "start_logit": -2.61328125,
            "end_logit": -4.8515625,
            "text": "lysine and arginine methyltransferases and proteins that recognise the methyl-lysine",
            "probability": 0.0
        }
    ],
    "6429b41757b1c7a315000004_7": [
        {
            "start_logit": 6.4296875,
            "end_logit": 3.322265625,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus.",
            "probability": 0.95361328125
        },
        {
            "start_logit": 6.4296875,
            "end_logit": 0.29833984375,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation",
            "probability": 0.04638671875
        },
        {
            "start_logit": -0.346923828125,
            "end_logit": 1.841796875,
            "text": "phosphorylation, acetylation, and methylation, which have profound effects on the remodeling of chromatin.",
            "probability": 0.00024700164794921875
        },
        {
            "start_logit": -0.346923828125,
            "end_logit": 0.29833984375,
            "text": "phosphorylation",
            "probability": 5.3048133850097656e-05
        },
        {
            "start_logit": -2.998046875,
            "end_logit": 1.841796875,
            "text": ".",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -7.63671875,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -8.15625,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications,",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -8.328125,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation, acetylation",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -8.96875,
            "text": "Histones",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -9.546875,
            "text": "Histones are",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -10.328125,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -7.25,
            "end_logit": 3.322265625,
            "text": ".",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -10.5390625,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation,",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -10.546875,
            "text": "Histones are the major protein constituent of chromatin in the eukaryotic nucleus. These proteins undergo a host of different post-translational modifications, including phosphorylation, acetylation,",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 6.4296875,
            "end_logit": -10.6953125,
            "text": "Histones are the major protein constituent of",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -7.609375,
            "end_logit": 1.841796875,
            "text": "remodeling of chromatin.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.25,
            "end_logit": 0.29833984375,
            "text": ". These proteins undergo a host of different post-translational modifications, including phosphorylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.346923828125,
            "end_logit": -6.625,
            "text": "phosphorylation, acetylation, and methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 3.322265625,
            "text": "protein constituent of chromatin in the eukaryotic nucleus.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.375,
            "end_logit": 1.841796875,
            "text": "acetylation, and methylation, which have profound effects on the remodeling of chromatin.",
            "probability": 5.960464477539063e-08
        }
    ],
    "6429b41757b1c7a315000004_8": [
        {
            "start_logit": 9.71875,
            "end_logit": 4.29296875,
            "text": "Recent studies have focused on histone arginine and lysine",
            "probability": 0.94921875
        },
        {
            "start_logit": 9.71875,
            "end_logit": 1.34375,
            "text": "Recent studies have focused on histone arginine and lysine methylation",
            "probability": 0.049530029296875
        },
        {
            "start_logit": 9.71875,
            "end_logit": -2.521484375,
            "text": "Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin",
            "probability": 0.0010356903076171875
        },
        {
            "start_logit": -1.255859375,
            "end_logit": 4.29296875,
            "text": "arginine and lysine",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 9.71875,
            "end_logit": -7.5390625,
            "text": "Recent",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 9.71875,
            "end_logit": -8.53125,
            "text": "Recent studies have focused on histone arginine and lysine methylation and",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": 9.71875,
            "end_logit": -8.6484375,
            "text": "Recent studies have focused on histone arginine",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -3.455078125,
            "end_logit": 4.29296875,
            "text": "histone arginine and lysine",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -1.255859375,
            "end_logit": 1.34375,
            "text": "arginine and lysine methylation",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -4.3984375,
            "end_logit": 4.29296875,
            "text": "lysine",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -10.15625,
            "text": "Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin. Concomitantly",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -10.640625,
            "text": "Recent studies have focused on histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin. Concomitantly,",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.71875,
            "end_logit": -10.6953125,
            "text": "Recent studies have focused on histone arginine and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.455078125,
            "end_logit": 1.34375,
            "text": "histone arginine and lysine methylation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.3984375,
            "end_logit": 1.34375,
            "text": "lysine methylation",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.255859375,
            "end_logit": -2.521484375,
            "text": "arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 4.29296875,
            "text": "and lysine",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 4.29296875,
            "text": "focused on histone arginine and lysine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 4.29296875,
            "text": "studies have focused on histone arginine and lysine",
            "probability": 0.0
        },
        {
            "start_logit": -3.455078125,
            "end_logit": -2.521484375,
            "text": "histone arginine and lysine methylation and the roles of these modifications in transcriptional regulation and the establishment of heterochromatin",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_0": [
        {
            "start_logit": 16.546875,
            "end_logit": 16.0625,
            "text": "iron homeostasis",
            "probability": 1.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -2.609375,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -3.8828125,
            "text": "iron homeostasis, is increased by iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.70703125,
            "end_logit": 16.0625,
            "text": "homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -4.8671875,
            "end_logit": 16.0625,
            "text": "Hepcidin, a key regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -6.4375,
            "text": "iron homeostasis, is increased by iron overload and inflammation",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -7.25390625,
            "text": "iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -7.40234375,
            "text": "iron homeostasis, is increased by iron overload and",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -7.80859375,
            "text": "iron homeostasis, is increased by iron overload and inflammation while suppressed by hypoxia.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3828125,
            "end_logit": 16.0625,
            "text": "of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 16.0625,
            "text": "a key regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 16.0625,
            "text": "key regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -8.6015625,
            "text": "iron homeostasis,",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -8.6953125,
            "text": "iron homeostasis, is increased by iron overload",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 16.0625,
            "text": ", a key regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 16.0625,
            "text": "regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -9.3203125,
            "text": "iron homeostasis, is increased",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -9.65625,
            "text": "iron homeostasis, is",
            "probability": 0.0
        },
        {
            "start_logit": 16.546875,
            "end_logit": -9.75,
            "text": "iron homeostasis, is increased by iron overload and inflammation while",
            "probability": 0.0
        },
        {
            "start_logit": -4.8671875,
            "end_logit": -2.609375,
            "text": "Hepcidin, a key regulator of iron",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_1": [
        {
            "start_logit": 16.421875,
            "end_logit": 15.8984375,
            "text": "iron homeostasis",
            "probability": 1.0
        },
        {
            "start_logit": 16.421875,
            "end_logit": -2.86328125,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.09765625,
            "end_logit": 15.8984375,
            "text": "Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -4.890625,
            "end_logit": 15.8984375,
            "text": "homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.421875,
            "end_logit": -6.06640625,
            "text": "iron homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 15.8984375,
            "text": "peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 15.8984375,
            "text": ", discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": 15.8984375,
            "text": "endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 15.8984375,
            "text": "discovered in the year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 15.8984375,
            "text": "an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 15.8984375,
            "text": "for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 15.8984375,
            "text": "is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 15.8984375,
            "text": ", is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 15.8984375,
            "text": "2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 15.8984375,
            "text": "the year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.8984375,
            "text": "in the year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.8984375,
            "text": "year 2000, is an endogenous peptide responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 15.8984375,
            "text": "responsible for iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -4.09765625,
            "end_logit": -2.86328125,
            "text": "Hepcidin, discovered in the year 2000, is an endogenous peptide responsible for iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.09765625,
            "end_logit": -4.71875,
            "text": "Hepcidin",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_2": [
        {
            "start_logit": 15.9609375,
            "end_logit": 13.9140625,
            "text": "iron homeostasis and metabolism",
            "probability": 1.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -3.552734375,
            "text": "iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -3.95703125,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": -3.369140625,
            "end_logit": 13.9140625,
            "text": "Recent data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 13.9140625,
            "text": "metabolism",
            "probability": 0.0
        },
        {
            "start_logit": 15.9609375,
            "end_logit": -7.94921875,
            "text": "iron homeostasis and",
            "probability": 0.0
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 13.9140625,
            "text": "homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 13.9140625,
            "text": "anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 13.9140625,
            "text": "and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 13.9140625,
            "text": "data suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 13.9140625,
            "text": "hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 13.9140625,
            "text": "is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 13.9140625,
            "text": "mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 13.9140625,
            "text": "major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 13.9140625,
            "text": "of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 13.9140625,
            "text": "a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.9140625,
            "text": "that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 13.9140625,
            "text": "and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 13.9140625,
            "text": "suggests that hepcidin is a major mediator of anemia and plays a central role in iron homeostasis and metabolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 13.9140625,
            "text": "in iron homeostasis and metabolism",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_3": [
        {
            "start_logit": 15.375,
            "end_logit": 15.0703125,
            "text": "iron homeostasis",
            "probability": 0.99609375
        },
        {
            "start_logit": 9.875,
            "end_logit": 15.0703125,
            "text": "iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis",
            "probability": 0.004070281982421875
        },
        {
            "start_logit": 15.375,
            "end_logit": -4.4296875,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -4.90234375,
            "text": "iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron",
            "probability": 0.0
        },
        {
            "start_logit": -6.01953125,
            "end_logit": 15.0703125,
            "text": "homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -1.916015625,
            "text": "iron export",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 15.0703125,
            "text": "The regulation of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -7.75,
            "text": "iron homeostasis hepcidin. Hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 15.0703125,
            "text": "export is controlled predominantly at the systemic level by the master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -8.7265625,
            "text": "iron homeostasis hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 15.0703125,
            "text": "regulation of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -9.1875,
            "text": "iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron demand",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -3.80859375,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -9.34375,
            "text": "iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron demand, making use of a range of regulatory mechanisms that center on the bone",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.0703125,
            "text": "of iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -9.3984375,
            "text": "iron homeostasis hepcidin.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 15.0703125,
            "text": "of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -4.4296875,
            "text": "iron export is controlled predominantly at the systemic level by the master regulator of iron",
            "probability": 0.0
        },
        {
            "start_logit": 15.375,
            "end_logit": -10.0625,
            "text": "iron homeostasis hepcidin. Hepcidin, in turn,",
            "probability": 0.0
        },
        {
            "start_logit": 9.875,
            "end_logit": -4.90234375,
            "text": "iron export is controlled predominantly at the systemic level by the master regulator of iron homeostasis hepcidin. Hepcidin, in turn, responds to changes in body iron",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_4": [
        {
            "start_logit": 15.578125,
            "end_logit": 11.6796875,
            "text": "iron",
            "probability": 1.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -8.140625,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -8.71875,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -9.3671875,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroport",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.3671875,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.53125,
            "text": "iron availability",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.5390625,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferro",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.546875,
            "text": "iron availability is controlled by the interaction of the iron",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.90625,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -10.9765625,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -11.5390625,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin,",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -11.7109375,
            "text": "iron availability is controlled by the interaction of the iron-regulatory hormone hepcidin with ferroportin, a",
            "probability": 0.0
        },
        {
            "start_logit": 15.578125,
            "end_logit": -11.7890625,
            "text": "iron availability is controlled by the interaction",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 11.6796875,
            "text": "In mammalian systems, iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 11.6796875,
            "text": ", iron",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -8.140625,
            "text": "ferroportin",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.140625,
            "text": "iron-regulatory hormone hepcidin with ferroportin",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -8.71875,
            "text": "ferroportin, a molecule that functions both as the hepcidin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -8.921875,
            "text": "ferroportin, a molecule that functions both as the hepcidin receptor as well as the sole known cellular export",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -8.71875,
            "text": "iron-regulatory hormone hepcidin with ferroportin, a molecule that functions both as the hepcidin receptor",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_5": [
        {
            "start_logit": 14.46875,
            "end_logit": 7.828125,
            "text": "iron export",
            "probability": 0.97900390625
        },
        {
            "start_logit": 14.46875,
            "end_logit": 3.98828125,
            "text": "iron export through ferroportin",
            "probability": 0.0209503173828125
        },
        {
            "start_logit": 14.46875,
            "end_logit": -1.7841796875,
            "text": "iron",
            "probability": 6.568431854248047e-05
        },
        {
            "start_logit": 14.46875,
            "end_logit": -4.02734375,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary iron",
            "probability": 6.9141387939453125e-06
        },
        {
            "start_logit": 14.46875,
            "end_logit": -4.41015625,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary iron.",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": 14.46875,
            "end_logit": -6.9453125,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.46875,
            "end_logit": -7.03125,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.2265625,
            "text": "iron export through ferroportin to blood plasma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.65625,
            "text": "iron export through ferroportin to blood plasma, hepcidin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.6640625,
            "text": "iron export through ferroport",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.4140625,
            "text": "iron export through ferroportin to",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.7890625,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of dietary",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.875,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.0,
            "text": "iron export through ferroportin to blood plasma,",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.1171875,
            "text": "iron export through ferro",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.7109375,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the absorption of",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.8984375,
            "text": "iron export through ferroportin to blood plasma, hepcidin inhibits the mobilization of iron from stores and the",
            "probability": 0.0
        },
        {
            "start_logit": -6.875,
            "end_logit": 7.828125,
            "text": "y reducing iron export",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 7.828125,
            "text": "export",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.828125,
            "text": "reducing iron export",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_6": [
        {
            "start_logit": 14.3046875,
            "end_logit": -1.490234375,
            "text": "iron",
            "probability": 0.6787109375
        },
        {
            "start_logit": 4.70703125,
            "end_logit": 7.35546875,
            "text": "iron metabolism",
            "probability": 0.320556640625
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.296875,
            "text": "iron deficiency anemia",
            "probability": 0.0007519721984863281
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -10.7109375,
            "text": "iron deficiency",
            "probability": 6.729364395141602e-05
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -11.609375,
            "text": "iron deficiency anemia is reported in this review",
            "probability": 2.7358531951904297e-05
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -12.3359375,
            "text": "iron deficiency anemia is",
            "probability": 1.329183578491211e-05
        },
        {
            "start_logit": 4.70703125,
            "end_logit": -4.203125,
            "text": "iron",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.734375,
            "end_logit": 7.35546875,
            "text": "metabolism",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 7.35546875,
            "text": "of iron metabolism",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": 7.35546875,
            "text": "the regulation of iron metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.515625,
            "end_logit": 7.35546875,
            "text": "biomarker for the regulation of iron metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 7.35546875,
            "text": "for the regulation of iron metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 7.35546875,
            "text": "hepcidin as a biomarker for the regulation of iron metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.53125,
            "end_logit": 7.35546875,
            "text": "regulation of iron metabolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -1.490234375,
            "text": "hepcidin and its possible significance as a biochemical parameter in iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -1.490234375,
            "text": "Information on the metabolism of hepcidin and its possible significance as a biochemical parameter in iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -1.490234375,
            "text": "metabolism of hepcidin and its possible significance as a biochemical parameter in iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -1.490234375,
            "text": "biochemical parameter in iron",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -1.490234375,
            "text": "the metabolism of hepcidin and its possible significance as a biochemical parameter in iron",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -4.203125,
            "text": "of iron",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_7": [
        {
            "start_logit": 8.265625,
            "end_logit": 10.890625,
            "text": "chronic renal failure anemia",
            "probability": 1.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": 10.890625,
            "text": "anemia",
            "probability": 8.285045623779297e-05
        },
        {
            "start_logit": -2.7421875,
            "end_logit": 10.890625,
            "text": "renal failure anemia",
            "probability": 1.6570091247558594e-05
        },
        {
            "start_logit": -4.5,
            "end_logit": 10.890625,
            "text": "Hepcidin is related to the pathogenesis of chronic renal failure anemia",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -8.3359375,
            "end_logit": 10.890625,
            "text": "failure anemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.265625,
            "end_logit": -7.890625,
            "text": "chronic renal",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.890625,
            "text": "the pathogenesis of chronic renal failure anemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 10.890625,
            "text": "related to the pathogenesis of chronic renal failure anemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 10.890625,
            "text": "pathogenesis of chronic renal failure anemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.125,
            "end_logit": 10.890625,
            "text": "is related to the pathogenesis of chronic renal failure anemia",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -8.546875,
            "text": "chronic renal failure anemia, which is",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -9.125,
            "text": "chronic renal failure anemia, which is considered a chronic inflammatory state",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -9.15625,
            "text": "chronic renal failure anemia, which is considered a chronic inflammatory",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -9.5234375,
            "text": "chronic",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -9.6796875,
            "text": "chronic renal failure",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -9.734375,
            "text": "chronic renal failure anemia,",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -10.7578125,
            "text": "chronic renal failure anemia, which",
            "probability": 0.0
        },
        {
            "start_logit": 8.265625,
            "end_logit": -11.71875,
            "text": "chronic renal failure anemia, which is considered a chronic",
            "probability": 0.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": -8.546875,
            "text": "anemia, which is",
            "probability": 0.0
        },
        {
            "start_logit": -1.134765625,
            "end_logit": -9.125,
            "text": "anemia, which is considered a chronic inflammatory state",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_8": [
        {
            "start_logit": 16.234375,
            "end_logit": 15.46875,
            "text": "Iron transport",
            "probability": 1.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -3.216796875,
            "text": "Iron",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 15.46875,
            "text": "transport",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -6.19140625,
            "text": "Iron transport across the human placenta",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -8.4296875,
            "text": "Iron transport across the human placenta is regulated by hepcidin.",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -8.6796875,
            "text": "Iron transport across the",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -8.890625,
            "text": "Iron transport across the human placenta is regulated by hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -9.515625,
            "text": "Iron transport across",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -10.109375,
            "text": "Iron transport across the human placenta is",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -10.65625,
            "text": "Iron transport across the human placenta is regulated",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -11.0,
            "text": "Iron transport across the human",
            "probability": 0.0
        },
        {
            "start_logit": 16.234375,
            "end_logit": -11.515625,
            "text": "Iron transport across the human placenta is regulated by",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -6.19140625,
            "text": "transport across the human placenta",
            "probability": 0.0
        },
        {
            "start_logit": -6.7421875,
            "end_logit": -6.19140625,
            "text": "placenta",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -8.4296875,
            "text": "transport across the human placenta is regulated by hepcidin.",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -8.6796875,
            "text": "transport across the",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -8.890625,
            "text": "transport across the human placenta is regulated by hepcidin",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -6.19140625,
            "text": "across the human placenta",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -6.19140625,
            "text": "the human placenta",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -9.515625,
            "text": "transport across",
            "probability": 0.0
        }
    ],
    "6422e7f0690f196b51000045_9": [
        {
            "start_logit": 16.609375,
            "end_logit": 16.265625,
            "text": "iron homeostasis",
            "probability": 1.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -1.6884765625,
            "text": "iron homeostasis, on regulation of iron transport",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -2.416015625,
            "text": "iron",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -2.47265625,
            "text": "iron homeostasis, on regulation of iron",
            "probability": 0.0
        },
        {
            "start_logit": -4.4921875,
            "end_logit": 16.265625,
            "text": "homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -5.51953125,
            "text": "iron homeostasis, on regulation of iron transport across trophoblast cells.",
            "probability": 0.0
        },
        {
            "start_logit": -5.8203125,
            "end_logit": 16.265625,
            "text": "hepcidin, a master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 16.265625,
            "text": "of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -7.80078125,
            "text": "iron homeostasis, on regulation of",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -8.0859375,
            "text": "iron homeostasis, on regulation",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -8.0859375,
            "text": "iron homeostasis, on regulation of iron transport across",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 16.265625,
            "text": "we investigate the role of hepcidin, a master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -8.3125,
            "text": "iron homeostasis, on regulation of iron transport across trophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 16.265625,
            "text": "master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.046875,
            "end_logit": 16.265625,
            "text": "regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 16.265625,
            "text": "a master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -9.0703125,
            "text": "iron homeostasis,",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 16.265625,
            "text": "the role of hepcidin, a master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 16.265625,
            "text": "investigate the role of hepcidin, a master regulator of iron homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": 16.609375,
            "end_logit": -9.7734375,
            "text": "iron homeostasis, on regulation of iron transport across trophoblast cells",
            "probability": 0.0
        }
    ],
    "63f57ea133942b094c000005_0": [
        {
            "start_logit": 9.1640625,
            "end_logit": 14.6328125,
            "text": "The classic clinical triad includes coloboma of the iris, ears, and anal malformations",
            "probability": 1.0
        },
        {
            "start_logit": -0.6796875,
            "end_logit": 14.6328125,
            "text": "coloboma of the iris, ears, and anal malformations",
            "probability": 5.3048133850097656e-05
        },
        {
            "start_logit": -2.791015625,
            "end_logit": 14.6328125,
            "text": "iris, ears, and anal malformations",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -5.5,
            "end_logit": 14.6328125,
            "text": "classic clinical triad includes coloboma of the iris, ears, and anal malformations",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 14.6328125,
            "text": "anal malformations",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 14.6328125,
            "text": "triad includes coloboma of the iris, ears, and anal malformations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 14.6328125,
            "text": "malformations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.109375,
            "end_logit": 14.6328125,
            "text": "clinical triad includes coloboma of the iris, ears, and anal malformations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.36328125,
            "end_logit": 14.6328125,
            "text": "includes coloboma of the iris, ears, and anal malformations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 14.6328125,
            "text": "oboma of the iris, ears, and anal malformations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.09375,
            "end_logit": 14.6328125,
            "text": "and anal malformations",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 14.6328125,
            "text": "ears, and anal malformations",
            "probability": 0.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -2.841796875,
            "text": "The classic clinical triad includes coloboma of the iris",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 14.6328125,
            "text": "oma of the iris, ears, and anal malformations",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 14.6328125,
            "text": ", ears, and anal malformations",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 14.6328125,
            "text": ", and anal malformations",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 14.6328125,
            "text": "22. The classic clinical triad includes coloboma of the iris, ears, and anal malformations",
            "probability": 0.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -4.3515625,
            "text": "The classic clinical triad",
            "probability": 0.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.19921875,
            "text": "The classic clinical triad includes coloboma of the iris, ears, and anal malformations.",
            "probability": 0.0
        },
        {
            "start_logit": 9.1640625,
            "end_logit": -5.2421875,
            "text": "The classic clinical triad includes coloboma",
            "probability": 0.0
        }
    ],
    "63f57ea133942b094c000005_1": [
        {
            "start_logit": 1.646484375,
            "end_logit": 12.6484375,
            "text": "The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 0.44482421875
        },
        {
            "start_logit": 1.5078125,
            "end_logit": 12.6484375,
            "text": "triad of iris coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 0.386474609375
        },
        {
            "start_logit": 0.68115234375,
            "end_logit": 12.6484375,
            "text": "iris coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 0.1688232421875
        },
        {
            "start_logit": -6.9921875,
            "end_logit": 12.6484375,
            "text": "classic triad of iris coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 7.861852645874023e-05
        },
        {
            "start_logit": -7.578125,
            "end_logit": 12.6484375,
            "text": "abnormalities",
            "probability": 4.374980926513672e-05
        },
        {
            "start_logit": -8.515625,
            "end_logit": 12.6484375,
            "text": "of iris coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -8.75,
            "end_logit": 12.6484375,
            "text": "anorectal malformations, and auricular abnormalities",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 12.6484375,
            "text": "coloboma, anorectal malformations, and auricular abnormalities",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -9.09375,
            "end_logit": 12.6484375,
            "text": "malformations, and auricular abnormalities",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": -9.140625,
            "end_logit": 12.6484375,
            "text": "and auricular abnormalities",
            "probability": 9.179115295410156e-06
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 12.6484375,
            "text": "auricular abnormalities",
            "probability": 8.940696716308594e-06
        },
        {
            "start_logit": -10.328125,
            "end_logit": 12.6484375,
            "text": ", anorectal malformations, and auricular abnormalities",
            "probability": 2.8014183044433594e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": 12.6484375,
            "text": "oma, anorectal malformations, and auricular abnormalities",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 1.646484375,
            "end_logit": -0.8828125,
            "text": "The classic triad of iris coloboma, anorectal malformations",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.5078125,
            "end_logit": -0.8828125,
            "text": "triad of iris coloboma, anorectal malformations",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 0.68115234375,
            "end_logit": -0.8828125,
            "text": "iris coloboma, anorectal malformations",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.646484375,
            "end_logit": -6.05859375,
            "text": "The classic triad",
            "probability": 0.0
        },
        {
            "start_logit": 1.5078125,
            "end_logit": -6.05859375,
            "text": "triad",
            "probability": 0.0
        },
        {
            "start_logit": 1.646484375,
            "end_logit": -7.37109375,
            "text": "The classic triad of iris coloboma",
            "probability": 0.0
        },
        {
            "start_logit": 1.646484375,
            "end_logit": -7.50390625,
            "text": "The classic triad of iris coloboma, anorectal malformations, and auricular",
            "probability": 0.0
        }
    ],
    "6429e17657b1c7a315000007_0": [
        {
            "start_logit": 13.5703125,
            "end_logit": 12.7734375,
            "text": "H3K27ac",
            "probability": 1.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -3.466796875,
            "text": "H3K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -5.65625,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": 12.7734375,
            "text": "and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -6.80859375,
            "text": "H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 12.7734375,
            "text": "enhancer expression and histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": 12.7734375,
            "text": "27ac",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -7.4453125,
            "text": "H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53 participated in regulating enhancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -7.51953125,
            "text": "H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": 12.7734375,
            "text": "ac",
            "probability": 0.0
        },
        {
            "start_logit": 13.5703125,
            "end_logit": -7.74609375,
            "text": "H3K27ac) revealed significantly higher level on Enhp53 than Enhno-p53 which suggested that p53 participated in regulating enhancer activity and chromatin structure.",
            "probability": 0.0
        },
        {
            "start_logit": -7.30859375,
            "end_logit": 12.7734375,
            "text": "enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 12.7734375,
            "text": "histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 12.7734375,
            "text": "H3K9ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 12.7734375,
            "text": "ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 12.7734375,
            "text": "H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": 12.7734375,
            "text": ", and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -5.12109375,
            "end_logit": -3.466796875,
            "text": "and H3K27",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": -3.466796875,
            "text": "enhancer expression and histone markers of enhancers (H3K4me1, H3K4me2, H3K4me3, H3K9ac, and H3K27",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": -3.466796875,
            "text": "27",
            "probability": 0.0
        }
    ],
    "6429e17657b1c7a315000007_1": [
        {
            "start_logit": 15.734375,
            "end_logit": 13.2578125,
            "text": "H3K27ac",
            "probability": 1.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -3.33203125,
            "text": "H3K27",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 15.734375,
            "end_logit": -4.08203125,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -5.45703125,
            "text": "H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -6.15625,
            "text": "H3K27ac), and active enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -6.5234375,
            "text": "H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K27",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -8.1640625,
            "text": "H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1) and H3K",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -8.6953125,
            "text": "H3K27ac),",
            "probability": 0.0
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 13.2578125,
            "text": "27ac",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 13.2578125,
            "text": "ac",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -9.484375,
            "text": "H3K27ac), and",
            "probability": 0.0
        },
        {
            "start_logit": 15.734375,
            "end_logit": -9.7109375,
            "text": "H3K27ac), and active enhancers can be identified by enrichments of both monomethylated H3K4 (H3K4me1",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": 13.2578125,
            "text": "transcription start sites of actively transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -7.80078125,
            "end_logit": 13.2578125,
            "text": "(H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 13.2578125,
            "text": "and acetylated H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": 13.2578125,
            "text": "acetylated H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 13.2578125,
            "text": "H3K4me3) and acetylated H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 13.2578125,
            "text": "H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 13.2578125,
            "text": "In general, transcription start sites of actively transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 13.2578125,
            "text": "transcribed genes are marked by trimethylated H3K4 (H3K4me3) and acetylated H3K27 (H3K27ac",
            "probability": 0.0
        }
    ],
    "6429e17657b1c7a315000007_2": [
        {
            "start_logit": 14.8359375,
            "end_logit": 14.3515625,
            "text": "H3K4me1",
            "probability": 1.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -3.892578125,
            "text": "H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -4.29296875,
            "text": "H3K4me",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": 14.3515625,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -5.84765625,
            "text": "H3K4me1, a chromatin hallmark of enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -6.01953125,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 14.3515625,
            "text": "me1",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 14.3515625,
            "text": "4me1",
            "probability": 0.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -8.6484375,
            "text": "H3K4me1,",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 14.3515625,
            "text": "marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4me1",
            "probability": 0.0
        },
        {
            "start_logit": 14.8359375,
            "end_logit": -10.5703125,
            "text": "H3K4me1, a chromatin hallmark of enhancers.",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -3.892578125,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": -6.76171875,
            "end_logit": -4.29296875,
            "text": "me",
            "probability": 0.0
        },
        {
            "start_logit": -5.34375,
            "end_logit": -5.84765625,
            "text": "1, a chromatin hallmark of enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -4.29296875,
            "text": "4me",
            "probability": 0.0
        },
        {
            "start_logit": -5.73828125,
            "end_logit": -5.84765625,
            "text": "enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -6.76171875,
            "end_logit": -5.84765625,
            "text": "me1, a chromatin hallmark of enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -6.30078125,
            "end_logit": -6.43359375,
            "text": "enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": -3.892578125,
            "text": "marks is expected. Actually, there exist contradictory reports about positive and negative correlations between DNA methylation and H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": -5.84765625,
            "text": "4me1, a chromatin hallmark of enhancers",
            "probability": 0.0
        }
    ],
    "6429e17657b1c7a315000007_3": [
        {
            "start_logit": 16.828125,
            "end_logit": 16.96875,
            "text": "H3K27ac",
            "probability": 1.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -1.912109375,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -4.0390625,
            "end_logit": 16.96875,
            "text": "ac",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -4.8125,
            "text": "H3K27",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 16.96875,
            "text": "27ac",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": 16.96875,
            "text": "the enrichment of H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -6.734375,
            "text": "H3K27ac, distinguishing active from primed enhancers",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 16.96875,
            "text": "enrichment of H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 16.96875,
            "text": "of H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 16.96875,
            "text": "regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -7.9375,
            "text": "H3K27ac,",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 16.96875,
            "text": "me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K27ac",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -8.59375,
            "text": "H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active enhancers",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -8.6484375,
            "text": "H3K27ac, distinguishing active",
            "probability": 0.0
        },
        {
            "start_logit": 16.828125,
            "end_logit": -9.1484375,
            "text": "H3K27ac, distinguishing active from primed enhancers, follows a plateau in the lower range of the intermediate DNA methylation level, corresponding to active",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": -1.912109375,
            "text": "the enrichment of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": -1.912109375,
            "text": "methylated regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": -1.912109375,
            "text": "enrichment of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -1.912109375,
            "text": "of H3K",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -1.912109375,
            "text": "regions are H3K4me3 enriched, while those with intermediate DNA methylation levels are progressively H3K4me1 enriched. Additionally, the enrichment of H3K",
            "probability": 0.0
        }
    ],
    "6415b6eb690f196b5100000b_0": [
        {
            "start_logit": 6.17578125,
            "end_logit": 4.87890625,
            "text": "wakefulness/sleep cycles, pain perception, and appetite",
            "probability": 0.9892578125
        },
        {
            "start_logit": 6.17578125,
            "end_logit": 0.302978515625,
            "text": "wakefulness/sleep cycles",
            "probability": 0.0102081298828125
        },
        {
            "start_logit": -3.185546875,
            "end_logit": 4.87890625,
            "text": "pain perception, and appetite",
            "probability": 8.52346420288086e-05
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -4.6875,
            "text": "wakefulness/sleep cycles, pain",
            "probability": 6.955862045288086e-05
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -4.953125,
            "text": "wakefulness/sleep",
            "probability": 5.334615707397461e-05
        },
        {
            "start_logit": -4.06640625,
            "end_logit": 4.87890625,
            "text": "appetite",
            "probability": 3.528594970703125e-05
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -6.44140625,
            "text": "wakefulness/sleep cycles, pain perception, and appetite.",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": -5.38671875,
            "end_logit": 4.87890625,
            "text": "sleep cycles, pain perception, and appetite",
            "probability": 9.417533874511719e-06
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -7.390625,
            "text": "wakefulness/sleep cycles, pain perception",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -7.4609375,
            "text": "wakefulness",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -7.5234375,
            "text": "wakefulness/sleep cycles,",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -7.015625,
            "end_logit": 4.87890625,
            "text": "orexin neurons. This neuronal system plays a role in regulating wakefulness/sleep cycles, pain perception, and appetite",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -7.140625,
            "end_logit": 4.87890625,
            "text": ", pain perception, and appetite",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -9.4765625,
            "text": "wakefulness/sleep cycles, pain perception,",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -9.5546875,
            "text": "wakefulness/",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 4.87890625,
            "text": "/sleep cycles, pain perception, and appetite",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.609375,
            "end_logit": 4.87890625,
            "text": "perception, and appetite",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 6.17578125,
            "end_logit": -10.2421875,
            "text": "wakefulness/sleep cycles, pain perception, and",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.390625,
            "end_logit": 4.87890625,
            "text": "cycles, pain perception, and appetite",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.84375,
            "end_logit": 4.87890625,
            "text": "and appetite",
            "probability": 1.1920928955078125e-07
        }
    ],
    "6415b6eb690f196b5100000b_1": [
        {
            "start_logit": 15.8984375,
            "end_logit": 16.125,
            "text": "Food intake",
            "probability": 1.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -3.84375,
            "text": "Food",
            "probability": 0.0
        },
        {
            "start_logit": -4.4765625,
            "end_logit": 16.125,
            "text": "intake",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -6.7890625,
            "text": "Food intake, in contrast, receives circadian",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -7.1875,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin and orexin.",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -7.546875,
            "text": "Food intake,",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -8.6953125,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -8.8203125,
            "text": "Food intake, in contrast,",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -9.046875,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin, insulin and orexin",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -9.125,
            "text": "Food intake, in contrast, receives circadian modulation",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -9.421875,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -9.734375,
            "text": "Food intake, in contrast",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -10.3671875,
            "text": "Food intake, in",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -10.4609375,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -10.7265625,
            "text": "Food intake, in contrast, receives circadian modulation through hormones",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -11.1328125,
            "text": "Food intake, in contrast, receives",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -11.2890625,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -11.3046875,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin,",
            "probability": 0.0
        },
        {
            "start_logit": 15.8984375,
            "end_logit": -11.3203125,
            "text": "Food intake, in contrast, receives circadian modulation through hormones such as leptin, ghrelin,",
            "probability": 0.0
        },
        {
            "start_logit": -4.4765625,
            "end_logit": -6.7890625,
            "text": "intake, in contrast, receives circadian",
            "probability": 0.0
        }
    ],
    "6415b6eb690f196b5100000b_2": [
        {
            "start_logit": 14.9375,
            "end_logit": 14.5078125,
            "text": "narcolepsy",
            "probability": 1.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -0.53662109375,
            "text": "narcolepsy type 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.9375,
            "end_logit": -5.51171875,
            "text": "narcol",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": 14.5078125,
            "text": "epsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -8.2109375,
            "text": "narcolepsy type",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 14.5078125,
            "text": "orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -9.34375,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of the disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 14.5078125,
            "text": "sufficient to diagnose narcolepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -10.0078125,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 14.5078125,
            "text": "diagnose narcolepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -10.03125,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 14.5078125,
            "text": "cerebrospinal fluid is sufficient to diagnose narcolepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -10.8359375,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -10.9296875,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -10.984375,
            "text": "narcolepsy type 1,",
            "probability": 0.0
        },
        {
            "start_logit": 14.9375,
            "end_logit": -11.4921875,
            "text": "narcolepsy type 1, being a highly specific and sensitive biomarker, and the irreversible loss of hypocretin neurons is responsible for the main symptoms of",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": -0.53662109375,
            "text": "epsy type 1",
            "probability": 0.0
        },
        {
            "start_logit": -6.4453125,
            "end_logit": -0.53662109375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": -0.53662109375,
            "text": "orexin-A in the cerebrospinal fluid is sufficient to diagnose narcolepsy type 1",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -0.53662109375,
            "text": "type 1",
            "probability": 0.0
        }
    ],
    "6415b6eb690f196b5100000b_3": [
        {
            "start_logit": 14.6015625,
            "end_logit": 15.21875,
            "text": "feeding behavior",
            "probability": 1.0
        },
        {
            "start_logit": -2.20703125,
            "end_logit": 15.21875,
            "text": "Orexins, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -2.630859375,
            "text": "feeding behavior and the sleep and wakefulness states.",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -4.3046875,
            "text": "feeding behavior and the sleep and wakefulness states",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -5.05859375,
            "text": "feeding behavior and the sleep",
            "probability": 0.0
        },
        {
            "start_logit": -5.71875,
            "end_logit": 15.21875,
            "text": "behavior",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -5.2265625,
            "text": "feeding",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -5.40234375,
            "text": "feeding behavior and the sleep and wakefulness",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 15.21875,
            "text": "the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 15.21875,
            "text": "of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 15.21875,
            "text": "neuropeptides involved in the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 15.21875,
            "text": "regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -8.0625,
            "text": "feeding behavior and",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 15.21875,
            "text": "excitatory neuropeptides involved in the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -8.328125,
            "text": "feeding behavior and the",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 15.21875,
            "text": "s, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 15.21875,
            "text": "are excitatory neuropeptides involved in the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 15.21875,
            "text": "in the regulation of feeding behavior",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -9.8125,
            "text": "feeding behavior and the sleep and",
            "probability": 0.0
        },
        {
            "start_logit": -2.20703125,
            "end_logit": -2.630859375,
            "text": "Orexins, or hypocretins, are excitatory neuropeptides involved in the regulation of feeding behavior and the sleep and wakefulness states.",
            "probability": 0.0
        }
    ],
    "6415b6eb690f196b5100000b_4": [
        {
            "start_logit": 6.51953125,
            "end_logit": 5.171875,
            "text": "feeding behavior",
            "probability": 0.9970703125
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -1.193359375,
            "text": "feeding behavior and energy homeostasis, reward",
            "probability": 0.0017261505126953125
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -2.10546875,
            "text": "feeding behavior and energy homeostasis",
            "probability": 0.0006918907165527344
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": 5.171875,
            "text": "sleep/wakefulness state regulation, feeding behavior",
            "probability": 0.0004162788391113281
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -3.130859375,
            "text": "feeding behavior and energy homeostasis, reward system",
            "probability": 0.0002486705780029297
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -6.47265625,
            "text": "feeding behavior and energy homeostasis, reward system,",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -6.08203125,
            "end_logit": 5.171875,
            "text": "behavior",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -1.193359375,
            "text": "sleep/wakefulness state regulation, feeding behavior and energy homeostasis, reward",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 5.171875,
            "text": "wakefulness state regulation, feeding behavior",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -9.4609375,
            "text": "feeding behavior and energy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -9.859375,
            "text": "feeding",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 5.171875,
            "text": "state regulation, feeding behavior",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -2.10546875,
            "text": "sleep/wakefulness state regulation, feeding behavior and energy homeostasis",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -10.015625,
            "text": "feeding behavior and energy homeostasis,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.51953125,
            "end_logit": -10.2421875,
            "text": "feeding behavior and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 5.171875,
            "text": ", feeding behavior",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.125,
            "end_logit": 5.171875,
            "text": "goal-directed behaviors, sleep/wakefulness state regulation, feeding behavior",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -2.6953125,
            "text": "sleep/wakefulness state",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.515625,
            "end_logit": 5.171875,
            "text": "/wakefulness state regulation, feeding behavior",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.2666015625,
            "end_logit": -3.130859375,
            "text": "sleep/wakefulness state regulation, feeding behavior and energy homeostasis, reward system",
            "probability": 1.1920928955078125e-07
        }
    ],
    "6415b6eb690f196b5100000b_5": [
        {
            "start_logit": 14.7109375,
            "end_logit": 14.578125,
            "text": "sleep initiation and maintenance",
            "probability": 1.0
        },
        {
            "start_logit": 14.7109375,
            "end_logit": -5.51171875,
            "text": "sleep",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 14.578125,
            "text": "maintenance",
            "probability": 0.0
        },
        {
            "start_logit": 14.7109375,
            "end_logit": -6.5234375,
            "text": "sleep initiation",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": 14.578125,
            "text": "orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": 14.578125,
            "text": "and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": 14.7109375,
            "end_logit": -7.83984375,
            "text": "sleep initiation and",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 14.578125,
            "text": "promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 14.578125,
            "text": "orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 14.578125,
            "text": "initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 14.578125,
            "text": "receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": 14.7109375,
            "end_logit": -8.9765625,
            "text": "sleep initiation and maintenance.",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 14.578125,
            "text": "peptides are diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 14.578125,
            "text": "both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 14.578125,
            "text": "mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 14.578125,
            "text": "and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 14.578125,
            "text": "receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 14.578125,
            "text": "diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep initiation and maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -6.85546875,
            "end_logit": -5.51171875,
            "text": "orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": -5.51171875,
            "text": "orexinergic peptides are diverse and are mediated by orexin-1 and orexin-2 receptors. Antagonists that target both receptors have been shown to promote sleep",
            "probability": 0.0
        }
    ],
    "6415c5d4690f196b51000014_0": [
        {
            "start_logit": 15.0546875,
            "end_logit": 14.3515625,
            "text": "Pembrolizumab",
            "probability": 1.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": 3.052734375,
            "text": "Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -5.2734375,
            "text": "Pembrolizumab for Treatment of Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -5.28125,
            "text": "Pembroliz",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -5.74609375,
            "text": "Pem",
            "probability": 0.0
        },
        {
            "start_logit": -5.23828125,
            "end_logit": 14.3515625,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -6.05078125,
            "text": "Pembr",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -6.16015625,
            "text": "Pembrolizumab for Treatment",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -6.25390625,
            "text": "Pembrolizumab for Treatment of",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -6.6640625,
            "text": "Pembrolizumab for Treatment of Metastatic Non",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -7.99609375,
            "text": "Pembroli",
            "probability": 0.0
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 14.3515625,
            "text": "olizumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": 14.3515625,
            "text": "FDA Approval Summary: Pembrolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 14.3515625,
            "text": "zumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.8828125,
            "end_logit": 14.3515625,
            "text": "brolizumab",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -8.890625,
            "text": "Pembrolizumab for",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -9.0,
            "text": "Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -9.078125,
            "text": "Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 14.3515625,
            "text": "Approval Summary: Pembrolizumab",
            "probability": 0.0
        },
        {
            "start_logit": 15.0546875,
            "end_logit": -10.703125,
            "text": "Pembrolizumab for Treatment of Metastatic Non-",
            "probability": 0.0
        }
    ],
    "6415c5d4690f196b51000014_1": [
        {
            "start_logit": 12.40625,
            "end_logit": 6.81640625,
            "text": "pembrolizumab",
            "probability": 0.98193359375
        },
        {
            "start_logit": 7.890625,
            "end_logit": 6.8046875,
            "text": "treatment of patients with metastatic non-small cell lung cancer",
            "probability": 0.010650634765625
        },
        {
            "start_logit": 7.5703125,
            "end_logit": 6.8046875,
            "text": "metastatic non-small cell lung cancer",
            "probability": 0.0077362060546875
        },
        {
            "start_logit": 12.40625,
            "end_logit": -6.328125,
            "text": "pembroliz",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -1.771484375,
            "end_logit": 6.81640625,
            "text": "On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 12.40625,
            "end_logit": -7.984375,
            "text": "pembr",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.40625,
            "end_logit": -8.4296875,
            "text": "pem",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.890625,
            "end_logit": -5.90625,
            "text": "treatment of patients with",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.890625,
            "end_logit": -6.44921875,
            "text": "treatment of patients with metastatic non",
            "probability": 0.0
        },
        {
            "start_logit": 7.5703125,
            "end_logit": -6.44921875,
            "text": "metastatic non",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 6.8046875,
            "text": "non-small cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 6.8046875,
            "text": "with metastatic non-small cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 6.81640625,
            "text": "umab",
            "probability": 0.0
        },
        {
            "start_logit": -6.453125,
            "end_logit": 6.8046875,
            "text": "of patients with metastatic non-small cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.4765625,
            "end_logit": 6.8046875,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.5859375,
            "end_logit": 6.8046875,
            "text": "patients with metastatic non-small cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": 7.890625,
            "end_logit": -8.515625,
            "text": "treatment",
            "probability": 0.0
        },
        {
            "start_logit": 7.890625,
            "end_logit": -8.6640625,
            "text": "treatment of patients",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 6.81640625,
            "text": "October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab",
            "probability": 0.0
        },
        {
            "start_logit": -7.765625,
            "end_logit": 6.81640625,
            "text": "the U.S. Food and Drug Administration (FDA) approved pembrolizumab",
            "probability": 0.0
        }
    ],
    "62008022c9dfcb9c0900001b_0": [
        {
            "start_logit": 9.640625,
            "end_logit": 9.25,
            "text": "Albumin-Bilirubin",
            "probability": 0.927734375
        },
        {
            "start_logit": 5.6171875,
            "end_logit": 10.734375,
            "text": "HCC",
            "probability": 0.0726318359375
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 9.25,
            "text": "Bilirubin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.65625,
            "end_logit": 10.734375,
            "text": "Independent factors associated with survival were previous HCC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.640625,
            "end_logit": -7.6640625,
            "text": "Albumin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.0234375,
            "text": "Albumin-Bilirubin (ALBI) grade-3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.640625,
            "end_logit": -8.171875,
            "text": "Albumin-",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 9.25,
            "text": "-Bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 10.734375,
            "text": "survival were previous HCC",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 10.734375,
            "text": "factors associated with survival were previous HCC",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -10.53125,
            "text": "Albumin-Bilirubin (ALBI) grade",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 9.25,
            "text": "95% CI 1.02-1.20, p = 0.01), Albumin-Bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 9.640625,
            "end_logit": -11.453125,
            "text": "Albumin-Bilirubin (ALBI) grade-3 (HR 2",
            "probability": 0.0
        },
        {
            "start_logit": 5.6171875,
            "end_logit": -10.984375,
            "text": "HCC treatment (HR 2.01, 95% CI 1.23-3.27, p = 0.005), bi-lobar disease",
            "probability": 0.0
        },
        {
            "start_logit": 5.6171875,
            "end_logit": -11.25,
            "text": "HCC treatment (HR",
            "probability": 0.0
        },
        {
            "start_logit": 5.6171875,
            "end_logit": -11.34375,
            "text": "HCC treatment (HR 2",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -8.0234375,
            "text": "Bilirubin (ALBI) grade-3",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -8.0234375,
            "text": "-Bilirubin (ALBI) grade-3",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -10.53125,
            "text": "Bilirubin (ALBI) grade",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": -8.171875,
            "text": "-",
            "probability": 0.0
        }
    ],
    "62008022c9dfcb9c0900001b_1": [
        {
            "start_logit": 13.5078125,
            "end_logit": 14.5078125,
            "text": "albumin-bilirubin",
            "probability": 1.0
        },
        {
            "start_logit": -5.15625,
            "end_logit": 14.5078125,
            "text": "bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -5.83203125,
            "text": "albumin",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -6.41796875,
            "text": "albumin-",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -6.828125,
            "text": "albumin-bilirubin grade",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -7.0390625,
            "text": "albumin-bilirubin grade (ALBI) and the microbiome in patients with hepatitis C",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 14.5078125,
            "text": "-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -8.1640625,
            "text": "albumin-bilirubin grade (ALBI) and the microbiome in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -8.2109375,
            "text": "albumin-bilirubin grade (ALBI) and the microbiome in patients with hepatitis C.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -8.265625,
            "text": "albumin-bilirubin grade (ALBI) and the microbiome in patients with hepatitis",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": 14.5078125,
            "text": "database to evaluate the relationship between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 14.5078125,
            "text": "each database to evaluate the relationship between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.5078125,
            "text": "used each database to evaluate the relationship between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.5078125,
            "text": "We used each database to evaluate the relationship between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.5078125,
            "text": "the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 14.5078125,
            "text": "the relationship between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -10.609375,
            "text": "albumin-bilirubin grade (ALBI) and the microbiome",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -10.8203125,
            "text": "albumin-bilirubin grade (ALBI) and the",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -11.7421875,
            "text": "albumin-bilirubin grade (ALBI) and",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -11.8203125,
            "text": "albumin-bilirubin grade (ALBI)",
            "probability": 0.0
        }
    ],
    "62008022c9dfcb9c0900001b_2": [
        {
            "start_logit": 14.4921875,
            "end_logit": 14.5703125,
            "text": "albumin-bilirubin",
            "probability": 1.0
        },
        {
            "start_logit": -5.203125,
            "end_logit": 14.5703125,
            "text": "bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -5.5,
            "text": "albumin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -5.62109375,
            "text": "albumin-",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.49609375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.65234375,
            "text": "albumin-bilirubin (ALBI) score",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 14.5703125,
            "text": "-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.7265625,
            "text": "albumin-bilirubin (ALBI) score and severity of port",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 14.5703125,
            "text": "Association between the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 14.5703125,
            "text": "the albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.7109375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.4765625,
            "text": "albumin-bilirubin (ALBI)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.609375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.8359375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -10.9765625,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -11.0625,
            "text": "albumin-bilirubin (ALBI) score and severity of",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -11.140625,
            "text": "albumin-bilirubin (ALBI) score and severity",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -11.1953125,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -11.2109375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data-mining analysis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -11.2734375,
            "text": "albumin-bilirubin (ALBI) score and severity of portopulmonary hypertension (PoP",
            "probability": 0.0
        }
    ],
    "62008022c9dfcb9c0900001b_3": [
        {
            "start_logit": 14.3671875,
            "end_logit": 14.203125,
            "text": "albumin-bilirubin",
            "probability": 1.0
        },
        {
            "start_logit": -4.97265625,
            "end_logit": 14.203125,
            "text": "bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -4.98046875,
            "end_logit": 14.203125,
            "text": "liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -5.359375,
            "text": "albumin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -5.734375,
            "text": "albumin-",
            "probability": 0.0
        },
        {
            "start_logit": -5.87890625,
            "end_logit": 14.203125,
            "text": "At the diagnosis of PoPH, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -6.77734375,
            "text": "albumin-bilirubin (ALBI) score.",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 14.203125,
            "text": "PoPH, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 14.203125,
            "text": "-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.1484375,
            "text": "albumin-bilirubin (ALBI) score",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 14.203125,
            "text": "the diagnosis of PoPH, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 14.203125,
            "text": "H, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 14.203125,
            "text": "function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 14.203125,
            "text": "of PoPH, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 14.203125,
            "text": "diagnosis of PoPH, liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.203125,
            "text": ", liver function was evaluated by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.203125,
            "text": "by albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.7734375,
            "text": "albumin-bilirubin (ALBI)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -11.5859375,
            "text": "albumin-bilirubin (ALBI",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -11.671875,
            "text": "albumin-bilirubin (",
            "probability": 0.0
        }
    ],
    "62008022c9dfcb9c0900001b_4": [
        {
            "start_logit": 11.40625,
            "end_logit": 13.0078125,
            "text": "albumin-bilirubin",
            "probability": 1.0
        },
        {
            "start_logit": 0.315185546875,
            "end_logit": 13.0078125,
            "text": "modified albumin-bilirubin",
            "probability": 1.531839370727539e-05
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 13.0078125,
            "text": "bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -6.34765625,
            "text": "albumin",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -8.703125,
            "text": "albumin-",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 13.0078125,
            "text": "-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 13.0078125,
            "text": "24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 13.0078125,
            "text": "13, and 24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 13.0078125,
            "text": ": Fourteen, 13, and 24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 13.0078125,
            "text": "classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 13.0078125,
            "text": ", 13, and 24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 13.0078125,
            "text": "Fourteen, 13, and 24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -9.7109375,
            "text": "albumin-bilirubin (mALBI) grade 1, 2a, and 2b",
            "probability": 0.0
        },
        {
            "start_logit": -11.359375,
            "end_logit": 13.0078125,
            "text": "and 24 patients were classified based on modified albumin-bilirubin",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.03125,
            "text": "albumin-bilirubin (mALBI)",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.6328125,
            "text": "albumin-bilirubin (mALBI) grade",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -11.4296875,
            "text": "albumin-bilirubin (mALBI) grade 1, 2a",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -11.5625,
            "text": "albumin-bilirubin (mALBI) grade 1",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -11.671875,
            "text": "albumin-bilirubin (mALBI) grade 1, 2a, and 2b, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -11.7421875,
            "text": "albumin-bilirubin (mALBI",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_0": [
        {
            "start_logit": 6.4921875,
            "end_logit": 5.66015625,
            "text": "prednisone",
            "probability": 0.9970703125
        },
        {
            "start_logit": 6.4921875,
            "end_logit": -0.14697265625,
            "text": "prednisone or cyclophosphamide",
            "probability": 0.0029811859130859375
        },
        {
            "start_logit": -5.51953125,
            "end_logit": 5.66015625,
            "text": "coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -7.11328125,
            "end_logit": 5.66015625,
            "text": "feline coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 1.548828125,
            "end_logit": -4.31640625,
            "text": "s FIP is an immune-mediated disease, treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.03125,
            "end_logit": 5.66015625,
            "text": "the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.4921875,
            "end_logit": -10.0234375,
            "text": "prednisone or cyclophosphamide may slow disease progression but do not produce a cure.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 6.4921875,
            "end_logit": -10.03125,
            "text": "prednisone or cyclophosphamide may",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.4375,
            "end_logit": 5.66015625,
            "text": "immune response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.671875,
            "end_logit": 5.66015625,
            "text": "Immune suppressive drugs such as prednisone",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.4921875,
            "end_logit": -10.5078125,
            "text": "prednisone or",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.548828125,
            "end_logit": -5.58984375,
            "text": "s",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 6.4921875,
            "end_logit": -11.0625,
            "text": "prednisone or cyclophosphamide may slow disease progression but do not produce a cure",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.421875,
            "end_logit": 5.66015625,
            "text": "FCoV). Immune suppressive drugs such as prednisone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 5.66015625,
            "text": "treatment is mainly aimed at controlling the immune response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 5.66015625,
            "text": "response triggered by the infection with the feline coronavirus (FCoV). Immune suppressive drugs such as prednisone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.51953125,
            "end_logit": -0.14697265625,
            "text": "coronavirus (FCoV). Immune suppressive drugs such as prednisone or cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": -5.6171875,
            "end_logit": -0.14697265625,
            "text": "cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 1.548828125,
            "end_logit": -7.78125,
            "text": "s FIP is an immune-mediated disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.11328125,
            "end_logit": -0.14697265625,
            "text": "feline coronavirus (FCoV). Immune suppressive drugs such as prednisone or cyclophosphamide",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_1": [
        {
            "start_logit": 11.5,
            "end_logit": 13.0078125,
            "text": "interferon",
            "probability": 1.0
        },
        {
            "start_logit": -2.86328125,
            "end_logit": 13.0078125,
            "text": "feline interferon",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -8.09375,
            "end_logit": 13.0078125,
            "text": "recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 13.0078125,
            "text": "as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 13.0078125,
            "text": "feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 13.0078125,
            "text": "A total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 13.0078125,
            "text": "total of 12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 13.0078125,
            "text": "FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 13.0078125,
            "text": "treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.0078125,
            "text": "of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.0078125,
            "text": "infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.0078125,
            "text": "a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.0078125,
            "text": "12 clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.0078125,
            "text": "clinically ill cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.0078125,
            "text": "cats previously diagnosed as feline infectious peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 13.0078125,
            "text": "peritonitis (FIP) were treated with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 13.0078125,
            "text": "with a combination of recombinant feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.5078125,
            "text": "interferon and glucocorticoid",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -11.4765625,
            "text": "interferon and glucocorticoid.",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -11.8984375,
            "text": "interferon and",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_2": [
        {
            "start_logit": 12.4609375,
            "end_logit": 9.53125,
            "text": "YPOTHESIS",
            "probability": 0.9990234375
        },
        {
            "start_logit": 12.4609375,
            "end_logit": 2.240234375,
            "text": "YPOTHESIS: Feline interferon-omega",
            "probability": 0.0006771087646484375
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -1.2978515625,
            "text": "YPOTHESIS: Feline interferon",
            "probability": 1.9669532775878906e-05
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -3.068359375,
            "text": "YPOTHESIS: Feline",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -4.9921875,
            "text": "YPOTHESIS: Feline interferon-omega (FeIFN-omega)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -5.65625,
            "text": "YPOTHESIS: Feline interferon-",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -6.1328125,
            "text": "Y",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 3.9296875,
            "end_logit": 2.240234375,
            "text": "Feline interferon-omega",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -7.046875,
            "text": "YPOT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -7.3671875,
            "text": "YPOTHE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -8.265625,
            "text": "YPOTHESIS: Feline interferon-omega (Fe",
            "probability": 0.0
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -8.4765625,
            "text": "YPOTHESIS: Feline interferon-omega (FeIFN",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 9.53125,
            "text": "SIS",
            "probability": 0.0
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -9.234375,
            "text": "YPOTHESIS: Feline interferon-omega (FeIFN-omega",
            "probability": 0.0
        },
        {
            "start_logit": 3.9296875,
            "end_logit": -1.2978515625,
            "text": "Feline interferon",
            "probability": 0.0
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -9.875,
            "text": "YPOTHESIS: Feline interferon-omega (",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 9.53125,
            "text": "POTHESIS",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": 9.53125,
            "text": "HESIS",
            "probability": 0.0
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -10.6796875,
            "text": "YPOTHESIS:",
            "probability": 0.0
        },
        {
            "start_logit": 12.4609375,
            "end_logit": -10.9375,
            "text": "YPOTHESIS: Feline interferon-omega (FeIFN-",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_3": [
        {
            "start_logit": 8.265625,
            "end_logit": 5.1484375,
            "text": "Feliserin",
            "probability": 0.95361328125
        },
        {
            "start_logit": 5.11328125,
            "end_logit": 5.1484375,
            "text": "antibiotics and passive immunization with Feliserin",
            "probability": 0.040924072265625
        },
        {
            "start_logit": 5.11328125,
            "end_logit": 3.236328125,
            "text": "antibiotics",
            "probability": 0.00603485107421875
        },
        {
            "start_logit": 8.265625,
            "end_logit": -6.5859375,
            "text": "Feliser",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 8.265625,
            "end_logit": -8.15625,
            "text": "Fel",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -6.5859375,
            "text": "antibiotics and passive immunization with Feliser",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -8.15625,
            "text": "antibiotics and passive immunization with Fel",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.46875,
            "end_logit": 5.1484375,
            "text": "in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.921875,
            "end_logit": 5.1484375,
            "text": "iserin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.703125,
            "end_logit": 5.1484375,
            "text": "glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 5.1484375,
            "text": "All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 5.1484375,
            "text": "immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 5.1484375,
            "text": "with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -10.7890625,
            "text": "antibiotics and passive immunization with",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 5.1484375,
            "text": "adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -11.0234375,
            "text": "antibiotics and passive",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 5.1484375,
            "text": "treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": 5.11328125,
            "end_logit": -11.1171875,
            "text": "antibiotics and passive immunization",
            "probability": 0.0
        },
        {
            "start_logit": -11.1796875,
            "end_logit": 5.1484375,
            "text": "cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        },
        {
            "start_logit": -11.296875,
            "end_logit": 5.1484375,
            "text": "received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_4": [
        {
            "start_logit": 15.0625,
            "end_logit": 14.1171875,
            "text": "Propentofylline",
            "probability": 1.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -5.484375,
            "text": "Prop",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -5.81640625,
            "text": "Propentofylline (PPF)",
            "probability": 0.0
        },
        {
            "start_logit": -5.26171875,
            "end_logit": 14.1171875,
            "text": "ylline",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -6.69140625,
            "text": "Propent",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -6.7265625,
            "text": "Propentof",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -8.2265625,
            "text": "Propentofylline (PPF",
            "probability": 0.0
        },
        {
            "start_logit": -7.375,
            "end_logit": 14.1171875,
            "text": "ofylline",
            "probability": 0.0
        },
        {
            "start_logit": -7.44921875,
            "end_logit": 14.1171875,
            "text": "entofylline",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -8.609375,
            "text": "Propentofylline (PPF) can decrease vasculitis",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -9.4609375,
            "text": "Propentofylline (PP",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -9.890625,
            "text": "Propentofylline (PPF) can",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -10.2734375,
            "text": "Propentofylline (",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -10.765625,
            "text": "Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -10.796875,
            "text": "Propentofylline (PPF) can decrease vasculitis,",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -10.96875,
            "text": "Propentofylline (PPF) can decrease",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -11.3046875,
            "text": "Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -11.3125,
            "text": "Propentofylline (PPF) can decrease vasculitis, and",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -11.328125,
            "text": "Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival time in cats with FIP, and increase their quality of life.",
            "probability": 0.0
        },
        {
            "start_logit": 15.0625,
            "end_logit": -11.421875,
            "text": "Propentofylline (PPF) can decrease vasculitis, and therefore prolong survival",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_5": [
        {
            "start_logit": 12.2890625,
            "end_logit": 9.3671875,
            "text": "PPF",
            "probability": 1.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -7.28125,
            "text": "PP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.3671875,
            "text": "F",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -10.75,
            "text": "PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -10.875,
            "text": "PPF does",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 9.3671875,
            "text": ", PPF",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -11.6796875,
            "text": "PPF does not appear to be an effective treatment option",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -11.84375,
            "text": "PPF does not appear",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -11.84375,
            "text": "PPF does not",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -11.890625,
            "text": "PPF does not appear to be an effective treatment option in cats with a late stage of the disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -11.96875,
            "text": "PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -12.03125,
            "text": "PPF does not appear to be an effective treatment option in",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -12.1484375,
            "text": "PPF does not appear to be an effective treatment option in cats with a late stage",
            "probability": 0.0
        },
        {
            "start_logit": 12.2890625,
            "end_logit": -12.1953125,
            "text": "PPF does not appear to",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -7.28125,
            "text": ", PP",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -8.6328125,
            "text": ",",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -10.75,
            "text": "F does not appear to be an effective treatment option in cats with a late stage of the disease FIP.",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -10.875,
            "text": "F does",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": -11.6796875,
            "text": "F does not appear to be an effective treatment option",
            "probability": 0.0
        },
        {
            "start_logit": -8.6796875,
            "end_logit": -10.75,
            "text": ", PPF does not appear to be an effective treatment option in cats with a late stage of the disease FIP.",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_6": [
        {
            "start_logit": 10.828125,
            "end_logit": 9.5625,
            "text": "Polyprenyl Immunostimulant",
            "probability": 1.0
        },
        {
            "start_logit": -2.740234375,
            "end_logit": 9.5625,
            "text": "Feline infectious peritonitis (FIP) is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 10.828125,
            "end_logit": -5.27734375,
            "text": "Polyprenyl",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.828125,
            "end_logit": -5.63671875,
            "text": "Polyprenyl Immunost",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.828125,
            "end_logit": -7.2578125,
            "text": "Polypren",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.01171875,
            "end_logit": 9.5625,
            "text": "ulant",
            "probability": 0.0
        },
        {
            "start_logit": -7.21875,
            "end_logit": 9.5625,
            "text": "dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 9.5625,
            "text": "yl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -8.71875,
            "text": "Polyprenyl Immunostim",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -8.8203125,
            "text": "Polyp",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 9.5625,
            "text": "renyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 9.5625,
            "text": "Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 9.5625,
            "text": "with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 9.5625,
            "text": "imulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 9.5625,
            "text": "infectious peritonitis (FIP) is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.2265625,
            "end_logit": 9.5625,
            "text": "fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 9.5625,
            "text": "disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 9.5625,
            "text": ") is considered a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 9.5625,
            "text": "FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 9.5625,
            "text": "a fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_7": [
        {
            "start_logit": 9.3203125,
            "end_logit": 7.94921875,
            "text": "Polyprenyl Immunostimulant",
            "probability": 1.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -5.87109375,
            "text": "Polypren",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -6.58984375,
            "text": "Polyprenyl Immunost",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -7.84765625,
            "text": "Polyprenyl Immunostim",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -8.015625,
            "text": "Polyprenyl",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.75390625,
            "end_logit": 7.94921875,
            "text": "Immunostimulant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 7.94921875,
            "text": "yl Immunostimulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 7.94921875,
            "text": "ulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -8.90625,
            "text": "Polyp",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.96875,
            "end_logit": 7.94921875,
            "text": "renyl Immunostimulant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 7.94921875,
            "text": "imulant",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -10.78125,
            "text": "Polyprenyl Immunostimulant on the survival times of three cats with the dry",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.09375,
            "text": "Polyprenyl Immunostimulant on the survival times of",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.234375,
            "text": "Polyprenyl Immunostimulant on the survival times of three cats with the dry form of",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.25,
            "text": "Polyprenyl Immunostimulant on",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.875,
            "text": "Polyprenyl Immunostimulant on the survival times of three",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.96875,
            "text": "Polyprenyl Immunostimulant on the survival times",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.96875,
            "text": "Polyprenyl Immunostimulant on the survival times of three cats with the dry form",
            "probability": 0.0
        },
        {
            "start_logit": 9.3203125,
            "end_logit": -11.9765625,
            "text": "Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritoniti",
            "probability": 0.0
        },
        {
            "start_logit": -6.75390625,
            "end_logit": -6.58984375,
            "text": "Immunost",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_8": [
        {
            "start_logit": 6.83203125,
            "end_logit": 6.81640625,
            "text": "Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 0.9677734375
        },
        {
            "start_logit": 3.41015625,
            "end_logit": 6.81640625,
            "text": "coronavirus",
            "probability": 0.0316162109375
        },
        {
            "start_logit": 1.556640625,
            "end_logit": 4.765625,
            "text": "GC376",
            "probability": 0.0006356239318847656
        },
        {
            "start_logit": -3.19921875,
            "end_logit": 6.81640625,
            "text": "feline coronavirus",
            "probability": 4.2557716369628906e-05
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -8.46875,
            "text": "Feline infectious peritonitis (FIP)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -9.03125,
            "text": "Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.46875,
            "end_logit": 6.81640625,
            "text": ") is a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 6.81640625,
            "text": "fatal disease caused by a virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 6.81640625,
            "text": "infectious peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.984375,
            "end_logit": 6.81640625,
            "text": "virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 4.765625,
            "text": "protease inhibitor, GC376",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.109375,
            "end_logit": 6.81640625,
            "text": "highly fatal disease caused by a virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1875,
            "end_logit": 6.81640625,
            "text": "disease caused by a virulent feline coronavirus",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -10.34375,
            "text": "Feline infectious peritonitis (FIP) is a highly fatal disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -10.40625,
            "text": "Feline",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.578125,
            "end_logit": 6.81640625,
            "text": "a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 6.81640625,
            "text": "FIP) is a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 6.81640625,
            "text": "peritonitis (FIP) is a highly fatal disease caused by a virulent feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -10.765625,
            "text": "Feline infectious peritonitis (FIP) is a highly fatal disease caused by a virulent",
            "probability": 0.0
        },
        {
            "start_logit": 6.83203125,
            "end_logit": -10.8046875,
            "text": "Feline infectious peritonitis (FIP) is",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_9": [
        {
            "start_logit": 8.484375,
            "end_logit": 10.765625,
            "text": "coronavirus",
            "probability": 1.0
        },
        {
            "start_logit": -4.625,
            "end_logit": 10.765625,
            "text": "Combination siRNA therapy against feline coronavirus",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 10.765625,
            "text": "feline coronavirus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 10.765625,
            "text": "siRNA therapy against feline coronavirus",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.484375,
            "end_logit": -6.65234375,
            "text": "coronavirus can delay the emergence of antiviral resistance in vitro.",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -6.97265625,
            "text": "coronavirus can delay the emergence of antiviral",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 10.765625,
            "text": "therapy against feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.09375,
            "text": "coronavirus can delay the emergence of antiviral resistance",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -8.28125,
            "text": "coronavirus can",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 10.765625,
            "text": "against feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -10.8984375,
            "text": "coronavirus can delay the emergence",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -11.3359375,
            "text": "coronavirus can delay the emergence of",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -11.375,
            "text": "coronavirus can delay the emergence of antiviral resistance in",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -11.7421875,
            "text": "coronavirus can delay the emergence of antiviral resistance in vitro",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -11.8984375,
            "text": "coronavirus can delay the",
            "probability": 0.0
        },
        {
            "start_logit": 8.484375,
            "end_logit": -11.9375,
            "text": "coronavirus can delay",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -6.65234375,
            "text": "antiviral resistance in vitro.",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -6.97265625,
            "text": "antiviral",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -8.09375,
            "text": "antiviral resistance",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": -6.6484375,
            "text": "Combination siRNA therapy",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_10": [
        {
            "start_logit": 5.71875,
            "end_logit": 7.890625,
            "text": "antiviral RNAi against FIPV",
            "probability": 0.8408203125
        },
        {
            "start_logit": 5.71875,
            "end_logit": 6.2265625,
            "text": "antiviral RNAi",
            "probability": 0.1591796875
        },
        {
            "start_logit": -5.0078125,
            "end_logit": 7.890625,
            "text": "RNAi against FIPV",
            "probability": 1.8417835235595703e-05
        },
        {
            "start_logit": -5.875,
            "end_logit": 7.890625,
            "text": "FIPV",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": 5.71875,
            "end_logit": -4.44921875,
            "text": "antiviral RNAi against FIPV.",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -5.0078125,
            "end_logit": 6.2265625,
            "text": "RNAi",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -8.40625,
            "end_logit": 7.890625,
            "text": "PV",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 5.71875,
            "end_logit": -7.4296875,
            "text": "antiviral",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 7.890625,
            "text": "therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 7.890625,
            "text": "potential therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.25,
            "end_logit": 7.890625,
            "text": "the potential therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.2890625,
            "end_logit": 7.890625,
            "text": "application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.3359375,
            "end_logit": 7.890625,
            "text": "these data inform the potential therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.4609375,
            "end_logit": 7.890625,
            "text": "data inform the potential therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.5234375,
            "end_logit": 7.890625,
            "text": "inform the potential therapeutic application of antiviral RNAi against FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.640625,
            "end_logit": 7.890625,
            "text": "against FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 6.2265625,
            "text": "therapeutic application of antiviral RNAi",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 6.2265625,
            "text": "potential therapeutic application of antiviral RNAi",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": 6.2265625,
            "text": "the potential therapeutic application of antiviral RNAi",
            "probability": 0.0
        },
        {
            "start_logit": -11.2890625,
            "end_logit": 6.2265625,
            "text": "application of antiviral RNAi",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_11": [
        {
            "start_logit": 0.55419921875,
            "end_logit": 4.73046875,
            "text": "FIPV",
            "probability": 0.9990234375
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -3.1484375,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference",
            "probability": 0.0003781318664550781
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 4.73046875,
            "text": "successful in vitro inhibition of FIPV",
            "probability": 0.0001195073127746582
        },
        {
            "start_logit": -8.546875,
            "end_logit": 4.73046875,
            "text": "inhibition of FIPV",
            "probability": 0.00011140108108520508
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -4.98046875,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh et al., 2011).",
            "probability": 6.0558319091796875e-05
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 4.73046875,
            "text": "PV",
            "probability": 4.678964614868164e-05
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -5.5078125,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi)",
            "probability": 3.5881996154785156e-05
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 4.73046875,
            "text": "the successful in vitro inhibition of FIPV",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": -11.15625,
            "end_logit": 4.73046875,
            "text": "reported the successful in vitro inhibition of FIPV",
            "probability": 8.225440979003906e-06
        },
        {
            "start_logit": -11.171875,
            "end_logit": 4.73046875,
            "text": "previously reported the successful in vitro inhibition of FIPV",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -11.21875,
            "end_logit": 4.73046875,
            "text": "We previously reported the successful in vitro inhibition of FIPV",
            "probability": 7.68899917602539e-06
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -8.9296875,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -9.96875,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -10.1015625,
            "text": "FIPV replication by",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.83203125,
            "end_logit": -3.1484375,
            "text": "RNA interference",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -10.890625,
            "text": "FIPV replication by synthetic siRNA",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -10.953125,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -10.9609375,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDonagh et al.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -11.1015625,
            "text": "FIPV replication",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.55419921875,
            "end_logit": -11.125,
            "text": "FIPV replication by synthetic siRNA mediated RNA interference (RNAi) in an immortalised cell line (McDona",
            "probability": 1.1920928955078125e-07
        }
    ],
    "64240f33690f196b51000049_12": [
        {
            "start_logit": 6.609375,
            "end_logit": 1.431640625,
            "text": "viroporin inhibitors",
            "probability": 0.998046875
        },
        {
            "start_logit": 6.609375,
            "end_logit": -5.55078125,
            "text": "viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.",
            "probability": 0.0009279251098632812
        },
        {
            "start_logit": 6.609375,
            "end_logit": -5.890625,
            "text": "viroporin",
            "probability": 0.0006604194641113281
        },
        {
            "start_logit": 6.609375,
            "end_logit": -6.62109375,
            "text": "viroporin inhibitors against feline infectious peritonitis virus",
            "probability": 0.00031948089599609375
        },
        {
            "start_logit": 6.609375,
            "end_logit": -10.0390625,
            "text": "vir",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 6.609375,
            "end_logit": -10.5859375,
            "text": "viropo",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -10.7734375,
            "text": "viroporin inhibitors against feline infectious peritonitis",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -10.8125,
            "text": "viroporin inhibitors against feline infectious peritonitis virus serotypes I and II",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -10.8359375,
            "text": "viroporin inhibitors against",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -11.03125,
            "text": "viroporin inhibitors against feline infectious peritonitis virus serotypes",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 1.431640625,
            "text": "Differential effects of viroporin inhibitors",
            "probability": 3.2186508178710938e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -11.328125,
            "text": "viroporin inhibitors against feline infectious peritonitis virus serotypes I and",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 6.609375,
            "end_logit": -11.390625,
            "text": "viroporin inhibitors against feline infectious peritonitis virus serotypes I",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -8.703125,
            "end_logit": 1.431640625,
            "text": "oporin inhibitors",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 1.431640625,
            "text": "rin inhibitors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 1.431640625,
            "text": "effects of viroporin inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 1.431640625,
            "text": "inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -4.4765625,
            "text": "Differential",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -5.55078125,
            "text": "Differential effects of viroporin inhibitors against feline infectious peritonitis virus serotypes I and II.",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -5.890625,
            "text": "Differential effects of viroporin",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_13": [
        {
            "start_logit": 14.3515625,
            "end_logit": 11.421875,
            "text": "HMA",
            "probability": 1.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -5.11328125,
            "text": "HMA and other viroporin inhibitors affect replication of FIPV",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -5.53125,
            "text": "HM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -8.8203125,
            "text": "HMA and other viroporin inhibitors affect replication of FIPV.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.296875,
            "text": "HMA and other viroporin inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": 11.421875,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -11.3203125,
            "text": "HMA and other viroporin inhibitors affect replication of FI",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -11.3671875,
            "text": "HMA and other viroporin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -11.5078125,
            "text": "HMA and other viroporin inhibitors affect replication",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -11.921875,
            "text": "HMA and other vir",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -11.984375,
            "text": "HMA and other viroporin inhibitors affect replication of",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -12.0703125,
            "text": "HMA and other viroporin inhibitors affect",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 11.421875,
            "text": "not clear whether HMA",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.421875,
            "text": "is not clear whether HMA",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.421875,
            "text": "it is not clear whether HMA",
            "probability": 0.0
        },
        {
            "start_logit": -7.12890625,
            "end_logit": -5.11328125,
            "text": "A and other viroporin inhibitors affect replication of FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -5.11328125,
            "text": "FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -7.859375,
            "end_logit": -5.11328125,
            "text": "PV",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": -5.11328125,
            "text": "viroporin inhibitors affect replication of FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -5.11328125,
            "text": "inhibitors affect replication of FIPV",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_14": [
        {
            "start_logit": 12.96875,
            "end_logit": 10.9140625,
            "text": "HMA",
            "probability": 1.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -6.33203125,
            "text": "HM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.96875,
            "end_logit": -7.3515625,
            "text": "HMA and other viroporin inhibitors (DIDS",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": 10.9140625,
            "text": "e examined the effect of HMA",
            "probability": 0.0
        },
        {
            "start_logit": 12.96875,
            "end_logit": -8.625,
            "text": "HMA and other viroporin inhibitors (DID",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 10.9140625,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -4.6640625,
            "text": "amantadine",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -6.33203125,
            "text": "e examined the effect of HM",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -6.5,
            "text": "e",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -7.3515625,
            "text": "e examined the effect of HMA and other viroporin inhibitors (DIDS",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -4.6640625,
            "text": "S [4,4'-disothiocyano-2,2'-stilbenedisulphonic acid] and amantadine",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": -7.3515625,
            "text": "A and other viroporin inhibitors (DIDS",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -8.625,
            "text": "e examined the effect of HMA and other viroporin inhibitors (DID",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": -7.3515625,
            "text": "DIDS",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -4.6640625,
            "text": "adine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -4.6640625,
            "text": "stilbenedisulphonic acid] and amantadine",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -8.8359375,
            "text": "amantadine) on infection by FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -4.6640625,
            "text": "acid] and amantadine",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": -8.625,
            "text": "A and other viroporin inhibitors (DID",
            "probability": 0.0
        },
        {
            "start_logit": -5.82421875,
            "end_logit": -9.90625,
            "text": "am",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_15": [
        {
            "start_logit": 14.0859375,
            "end_logit": 12.828125,
            "text": "DIDS",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -6.38671875,
            "text": "DID",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -6.48828125,
            "text": "DIDS treatment decreased the titer of FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 12.828125,
            "text": "S",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.828125,
            "text": "DIDS treatment",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.1015625,
            "text": "DIDS treatment decreased the titer of FI",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 12.828125,
            "text": ", DIDS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.3046875,
            "text": "DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner,",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.6484375,
            "text": "DIDS treatment decreased the titer of FIPV serotype II strain",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.7890625,
            "text": "DIDS treatment decreased",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 12.828125,
            "text": "In contrast, DIDS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.796875,
            "text": "DIDS treatment decreased the",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.8515625,
            "text": "DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.890625,
            "text": "DIDS treatment decreased the titer of FIPV serotype II strain 79-1146 in dose-dependent manner, but it only",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.828125,
            "text": "contrast, DIDS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -11.0703125,
            "text": "DIDS treatment decreased the titer of",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -11.0859375,
            "text": "DIDS treatment decreased the titer of FIPV serotype II",
            "probability": 0.0
        },
        {
            "start_logit": -5.96484375,
            "end_logit": -6.48828125,
            "text": "FIPV",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -6.48828125,
            "text": "PV",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": -6.48828125,
            "text": "S treatment decreased the titer of FIPV",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_16": [
        {
            "start_logit": 11.125,
            "end_logit": 11.8046875,
            "text": "Coronavirus",
            "probability": 1.0
        },
        {
            "start_logit": -3.625,
            "end_logit": 11.8046875,
            "text": "Reversal of the Progression of Fatal Coronavirus",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 11.125,
            "end_logit": -7.1484375,
            "text": "Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -7.40625,
            "text": "Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -8.546875,
            "text": "Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 11.8046875,
            "text": "Fatal Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -9.3046875,
            "text": "Coronavirus Infection",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -9.6640625,
            "text": "Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.8046875,
            "text": "Progression of Fatal Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.8046875,
            "text": "the Progression of Fatal Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -10.8046875,
            "text": "Coronavirus Infection in Cats by",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -11.328125,
            "text": "Coronavirus Infection in Cats by a",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -11.5546875,
            "text": "Coronavirus Infection in",
            "probability": 0.0
        },
        {
            "start_logit": 11.125,
            "end_logit": -12.1015625,
            "text": "Coronavirus Infection in Cats by a Broad-",
            "probability": 0.0
        },
        {
            "start_logit": -3.625,
            "end_logit": -6.109375,
            "text": "Reversal",
            "probability": 0.0
        },
        {
            "start_logit": -3.625,
            "end_logit": -7.1484375,
            "text": "Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -3.625,
            "end_logit": -7.40625,
            "text": "Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -3.625,
            "end_logit": -8.546875,
            "text": "Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease",
            "probability": 0.0
        },
        {
            "start_logit": -5.31640625,
            "end_logit": -7.1484375,
            "text": "Coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -5.31640625,
            "end_logit": -7.40625,
            "text": "Coronavirus Protease Inhibitor",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_17": [
        {
            "start_logit": 4.8203125,
            "end_logit": 2.4609375,
            "text": "antiviral",
            "probability": 1.0
        },
        {
            "start_logit": 4.8203125,
            "end_logit": -9.703125,
            "text": "antiviral treatment led to full recovery of cats when treatment was started at a stage of disease",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 4.8203125,
            "end_logit": -11.0703125,
            "text": "antiviral treatment",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 4.8203125,
            "end_logit": -11.578125,
            "text": "antiviral treatment led to full recovery of cats when treatment was started at a stage",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.8203125,
            "end_logit": -11.6171875,
            "text": "antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.8203125,
            "end_logit": -11.6484375,
            "text": "antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 2.4609375,
            "text": "FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.203125,
            "end_logit": 2.4609375,
            "text": "FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.578125,
            "end_logit": 2.4609375,
            "text": "ro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 2.4609375,
            "text": "Lpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 2.4609375,
            "text": ". Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.96875,
            "end_logit": 2.4609375,
            "text": "certain clinical and laboratory signs become apparent. We found that antiviral",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.5,
            "end_logit": -7.64453125,
            "text": "3CLpro inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -9.2421875,
            "text": "3CLpro",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": -9.3359375,
            "text": "3CLpro inhibitor in laboratory cats with FIP.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -7.64453125,
            "text": "our 3CLpro inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -7.64453125,
            "text": "ro inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -7.64453125,
            "text": "Lpro inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": -7.64453125,
            "text": "therapeutic efficacy of our 3CLpro inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -9.703125,
            "text": "disease",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_18": [
        {
            "start_logit": 10.9921875,
            "end_logit": 7.265625,
            "text": "TNF-alpha monoclonal antibody",
            "probability": 0.99609375
        },
        {
            "start_logit": 10.9921875,
            "end_logit": 1.7353515625,
            "text": "TNF",
            "probability": 0.003978729248046875
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -5.046875,
            "text": "TNF-alpha",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -6.41015625,
            "text": "TNF-alpha monoclonal",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 7.265625,
            "text": "anti-feline TNF-alpha monoclonal antibody",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.04296875,
            "end_logit": 7.265625,
            "text": "antibody",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -8.921875,
            "text": "TNF-alpha monoclonal antibody for feline infectious peritonitis.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -9.1328125,
            "text": "TNF-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 7.265625,
            "text": "feline TNF-alpha monoclonal antibody",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -11.1875,
            "text": "TNF-alpha monoclonal antibody for",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -11.34375,
            "text": "TNF-alpha monoclonal antibody for feline infectious peritonitis",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 7.265625,
            "text": "alpha monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 7.265625,
            "text": "monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 7.265625,
            "text": "Therapeutic effect of anti-feline TNF-alpha monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -4.80078125,
            "end_logit": 1.7353515625,
            "text": "anti-feline TNF",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 7.265625,
            "text": "-feline TNF-alpha monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -11.4921875,
            "end_logit": 7.265625,
            "text": "effect of anti-feline TNF-alpha monoclonal antibody",
            "probability": 0.0
        },
        {
            "start_logit": -6.0859375,
            "end_logit": 1.7353515625,
            "text": "feline TNF",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 1.7353515625,
            "text": "Therapeutic effect of anti-feline TNF",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 1.7353515625,
            "text": "-feline TNF",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_19": [
        {
            "start_logit": 3.04296875,
            "end_logit": 3.466796875,
            "text": "fTNF-alpha antibody",
            "probability": 0.9697265625
        },
        {
            "start_logit": -0.63671875,
            "end_logit": 3.466796875,
            "text": "anti-fTNF-alpha antibody",
            "probability": 0.0245208740234375
        },
        {
            "start_logit": -2.4140625,
            "end_logit": 3.466796875,
            "text": "the anti-fTNF-alpha antibody",
            "probability": 0.004154205322265625
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -3.52734375,
            "text": "fTNF-alpha",
            "probability": 0.0008912086486816406
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -4.140625,
            "text": "fTNF-alpha antibody is effective for the treatment of FIP.",
            "probability": 0.00048279762268066406
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 3.466796875,
            "text": "antibody",
            "probability": 4.011392593383789e-05
        },
        {
            "start_logit": -0.63671875,
            "end_logit": -3.52734375,
            "text": "anti-fTNF-alpha",
            "probability": 2.2470951080322266e-05
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -7.21484375,
            "text": "fTNF",
            "probability": 2.2292137145996094e-05
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -7.3515625,
            "text": "fTNF-",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -7.96484375,
            "end_logit": 3.466796875,
            "text": "NF-alpha antibody",
            "probability": 1.609325408935547e-05
        },
        {
            "start_logit": -0.63671875,
            "end_logit": -4.140625,
            "text": "anti-fTNF-alpha antibody is effective for the treatment of FIP.",
            "probability": 1.2278556823730469e-05
        },
        {
            "start_logit": -8.453125,
            "end_logit": 3.466796875,
            "text": "alpha antibody",
            "probability": 9.894371032714844e-06
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -8.3984375,
            "text": "fTNF-alpha antibody is",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": -2.4140625,
            "end_logit": -3.52734375,
            "text": "the anti-fTNF-alpha",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 3.466796875,
            "text": "-fTNF-alpha antibody",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -2.4140625,
            "end_logit": -4.140625,
            "text": "the anti-fTNF-alpha antibody is effective for the treatment of FIP.",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -9.8828125,
            "text": "fT",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 3.04296875,
            "end_logit": -10.21875,
            "text": "fTNF-alpha antibody is effective for the treatment of FIP",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 3.466796875,
            "text": "-alpha antibody",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 3.466796875,
            "text": "strongly suggested that the anti-fTNF-alpha antibody",
            "probability": 1.0728836059570312e-06
        }
    ],
    "64240f33690f196b51000049_20": [
        {
            "start_logit": 10.90625,
            "end_logit": 11.8046875,
            "text": "GS-441524",
            "probability": 1.0
        },
        {
            "start_logit": -2.1796875,
            "end_logit": 11.8046875,
            "text": "Antiviral treatment using the adenosine nucleoside analogue GS-441524",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -5.875,
            "end_logit": 11.8046875,
            "text": "24",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.90625,
            "end_logit": -6.12109375,
            "text": "GS-",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.05078125,
            "text": "GS-4415",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.09765625,
            "text": "GS-44",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 11.8046875,
            "text": "adenosine nucleoside analogue GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 11.8046875,
            "text": "441524",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 11.8046875,
            "text": "the adenosine nucleoside analogue GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 11.8046875,
            "text": "1524",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 11.8046875,
            "text": "-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -7.8203125,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 11.8046875,
            "text": "analogue GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 11.8046875,
            "text": "treatment using the adenosine nucleoside analogue GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 11.8046875,
            "text": "nucleoside analogue GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -10.40625,
            "text": "GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -11.09375,
            "text": "GS-441524 in",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -11.484375,
            "text": "GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -11.765625,
            "text": "GS-441524 in cats with clinically diagnosed neurological",
            "probability": 0.0
        },
        {
            "start_logit": 10.90625,
            "end_logit": -12.1171875,
            "text": "GS-441524 in cats with clinically diagnosed neurological feline",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_21": [
        {
            "start_logit": 14.2734375,
            "end_logit": 15.796875,
            "text": "GS-441524",
            "probability": 1.0
        },
        {
            "start_logit": -5.1875,
            "end_logit": 15.796875,
            "text": "24",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": 15.796875,
            "text": "with GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -5.9609375,
            "text": "GS-",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 15.796875,
            "text": "441524",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 15.796875,
            "text": "Treatment with GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -6.25390625,
            "text": "GS-4415",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -6.28125,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 15.796875,
            "text": "-441524",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 15.796875,
            "text": "1524",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -6.734375,
            "text": "GS-44",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -8.4609375,
            "text": "GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -8.4765625,
            "text": "GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological FIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.7109375,
            "text": "GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological FI",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.9453125,
            "text": "GS-441524 shows clinical efficacy and may result in clearance and long-term resolution of neurological",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.984375,
            "text": "GS-441524 shows clinical efficacy and may",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.0546875,
            "text": "GS-441524 shows clinical efficacy and may result in clearance",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.71875,
            "text": "GS-441524 shows clinical efficacy and may result in clearance and long-term resolution",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -11.1171875,
            "text": "GS-441524 shows",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": -5.9609375,
            "text": "with GS-",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_22": [
        {
            "start_logit": 14.75,
            "end_logit": 13.125,
            "text": "Mutian\u00ae Xraphconn",
            "probability": 1.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -3.20703125,
            "text": "Mutian\u00ae Xraphconn (Mutian X)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.75,
            "end_logit": -5.29296875,
            "text": "Mutian\u00ae Xr",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -6.03515625,
            "text": "Mut",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -7.203125,
            "text": "Mutian",
            "probability": 0.0
        },
        {
            "start_logit": -5.8984375,
            "end_logit": 13.125,
            "text": "Xraphconn",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -7.53125,
            "text": "Mutian\u00ae Xraph",
            "probability": 0.0
        },
        {
            "start_logit": -6.171875,
            "end_logit": 13.125,
            "text": "n",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -8.3203125,
            "text": "Mutian\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -8.390625,
            "text": "Mutian\u00ae Xraphconn (Mutian X",
            "probability": 0.0
        },
        {
            "start_logit": -7.125,
            "end_logit": 13.125,
            "text": "ian\u00ae Xraphconn",
            "probability": 0.0
        },
        {
            "start_logit": -7.24609375,
            "end_logit": 13.125,
            "text": "aphconn",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -8.90625,
            "text": "Mutian\u00ae Xraphcon",
            "probability": 0.0
        },
        {
            "start_logit": -7.37890625,
            "end_logit": 13.125,
            "text": "\u00ae Xraphconn",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 13.125,
            "text": "conn",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -10.0859375,
            "text": "Mutian\u00ae Xraphconn (",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -10.2421875,
            "text": "Mutian\u00ae Xraphconn (Mutian",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -11.1015625,
            "text": "Mutian\u00ae Xraphconn (Mutian X) is a product marketed",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -11.1875,
            "text": "Mutian\u00ae Xraphconn (Mutian X) is a product marketed to treat cats with FIP but is also being used to stop virus",
            "probability": 0.0
        },
        {
            "start_logit": 14.75,
            "end_logit": -11.2890625,
            "text": "Mutian\u00ae Xraphconn (Mut",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_23": [
        {
            "start_logit": 15.8125,
            "end_logit": 16.515625,
            "text": "Mutian\u00aeX",
            "probability": 1.0
        },
        {
            "start_logit": -2.845703125,
            "end_logit": 16.515625,
            "text": "Oral Mutian\u00aeX",
            "probability": 0.0
        },
        {
            "start_logit": -4.42578125,
            "end_logit": 16.515625,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -4.23046875,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -4.37109375,
            "text": "Mut",
            "probability": 0.0
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 16.515625,
            "text": "ian\u00aeX",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -6.390625,
            "text": "Mutian",
            "probability": 0.0
        },
        {
            "start_logit": -7.16015625,
            "end_logit": 16.515625,
            "text": "\u00aeX",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -7.23046875,
            "text": "Mutian\u00ae",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -7.890625,
            "text": "Mutian\u00aeX stopped",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -8.1796875,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus shedding",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -8.5,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats.",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -9.546875,
            "text": "Mutian\u00aeX stopped faecal",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -9.7734375,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected cats",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -9.8125,
            "text": "Mutian\u00aeX stopped faecal feline",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -9.8359375,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally infected",
            "probability": 0.0
        },
        {
            "start_logit": 15.8125,
            "end_logit": -11.0234375,
            "text": "Mutian\u00aeX stopped faecal feline coronavirus shedding by naturally",
            "probability": 0.0
        },
        {
            "start_logit": -2.845703125,
            "end_logit": -3.326171875,
            "text": "Oral",
            "probability": 0.0
        },
        {
            "start_logit": -2.845703125,
            "end_logit": -4.23046875,
            "text": "Oral Mutian\u00aeX stopped faecal feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -2.845703125,
            "end_logit": -4.37109375,
            "text": "Oral Mut",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_24": [
        {
            "start_logit": 15.125,
            "end_logit": 14.046875,
            "text": "Mefloquine",
            "probability": 1.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -4.9140625,
            "text": "Me",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -6.078125,
            "text": "Mefl",
            "probability": 0.0
        },
        {
            "start_logit": -5.1328125,
            "end_logit": 14.046875,
            "text": "oquine",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": 14.046875,
            "text": "Oral Administration of Mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": 14.046875,
            "text": "floquine",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 14.046875,
            "text": "Pharmacokinetic Profile of Oral Administration of Mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": -9.21875,
            "end_logit": 14.046875,
            "text": "of Mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.34375,
            "text": "Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.6328125,
            "text": "Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP).",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.65625,
            "text": "Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.6875,
            "text": "Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.6875,
            "text": "Mefloquine to Clinically Normal",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.6953125,
            "text": "Mefloquine to",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.8203125,
            "text": "Mefloquine to Clinically Normal Cats",
            "probability": 0.0
        },
        {
            "start_logit": 15.125,
            "end_logit": -10.8671875,
            "text": "Mefloquine to Clinically Normal Cats:",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -4.9140625,
            "text": "Oral Administration of Me",
            "probability": 0.0
        },
        {
            "start_logit": -6.90625,
            "end_logit": -6.078125,
            "text": "Oral Administration of Mefl",
            "probability": 0.0
        },
        {
            "start_logit": -7.0859375,
            "end_logit": -6.078125,
            "text": "fl",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -4.9140625,
            "text": "Pharmacokinetic Profile of Oral Administration of Me",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_25": [
        {
            "start_logit": 14.8828125,
            "end_logit": 13.7578125,
            "text": "mefloquine",
            "probability": 1.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -5.203125,
            "text": "me",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -5.71484375,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -5.15625,
            "end_logit": 13.7578125,
            "text": "oquine",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -6.43359375,
            "text": "mefl",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": 13.7578125,
            "text": "floquine",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -9.6328125,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -10.53125,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 13.7578125,
            "text": "pharmacokinetic profile of mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.7578125,
            "text": "The pharmacokinetic profile of mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -10.8046875,
            "text": "mefloquine was investigated as a preliminary study",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -10.8359375,
            "text": "mefloquine was",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 13.7578125,
            "text": "of mefloquine",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.0,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.203125,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment for",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.2109375,
            "text": "mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis)",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.25,
            "text": "mefloquine was investigated as a preliminary",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.265625,
            "text": "mefloquine was investigated as a",
            "probability": 0.0
        },
        {
            "start_logit": -5.15625,
            "end_logit": -5.71484375,
            "text": "oquine was investigated as a preliminary study towards a potential treatment for feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -5.58984375,
            "end_logit": -5.71484375,
            "text": "coronavirus",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_26": [
        {
            "start_logit": 15.3125,
            "end_logit": 14.4375,
            "text": "Mefloquine",
            "probability": 1.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -3.2734375,
            "text": "Mefloquine may provide a safe effective treatment for feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -4.75,
            "text": "Me",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": 14.4375,
            "text": "oquine",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -6.328125,
            "text": "Mefl",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -6.9453125,
            "text": "Mefloquine may",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -7.66015625,
            "text": "Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -7.765625,
            "text": "Mefloquine may provide a safe effective treatment for feline coronavirus and",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": 14.4375,
            "text": "floquine",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.0859375,
            "text": "Mefloquine may provide a safe effective treatment",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.140625,
            "text": "Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.171875,
            "text": "Mefloquine may provide a safe",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.1875,
            "text": "Mefloquine may provide a safe effective treatment for",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.3515625,
            "text": "Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.375,
            "text": "Mefloquine may provide a safe effective",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -10.4375,
            "text": "Mefloquine may provide a safe effective treatment for feline",
            "probability": 0.0
        },
        {
            "start_logit": 15.3125,
            "end_logit": -11.078125,
            "text": "Mefloquine may provide",
            "probability": 0.0
        },
        {
            "start_logit": -3.630859375,
            "end_logit": -3.2734375,
            "text": "coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -5.046875,
            "end_logit": -3.2734375,
            "text": "oquine may provide a safe effective treatment for feline coronavirus",
            "probability": 0.0
        },
        {
            "start_logit": -6.94921875,
            "end_logit": -3.2734375,
            "text": "floquine may provide a safe effective treatment for feline coronavirus",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_27": [
        {
            "start_logit": 15.2109375,
            "end_logit": 12.828125,
            "text": "itraconazole",
            "probability": 1.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -11.515625,
            "text": "itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -11.625,
            "text": "itraconazole partly",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -11.765625,
            "text": "itraconazole partly exerted a beneficial effect in a cat with FIP.",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -11.875,
            "text": "itraconazole partly exerted a beneficial effect in a cat",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 12.828125,
            "text": ", itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.0234375,
            "text": "itraconazole partly exerted a beneficial",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.078125,
            "text": "itraconazole partly exerted a beneficial effect in a cat with FIP",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.15625,
            "text": "itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment is warranted.",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.15625,
            "text": "itraconazole partly exerted",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.1640625,
            "text": "itraconazole partly exerted a beneficial effect in a cat with",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.2265625,
            "text": "itraconazole partly exerted a beneficial effect",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.2734375,
            "text": "itraconazole partly exerted a beneficial effect in",
            "probability": 0.0
        },
        {
            "start_logit": 15.2109375,
            "end_logit": -12.328125,
            "text": "itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole in FIP treatment",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 12.828125,
            "text": "In conclusion, itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": -10.375,
            "text": ",",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": -10.375,
            "text": "In conclusion,",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -11.515625,
            "text": "FIP. However, further investigation of a possible role of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -11.515625,
            "text": "cat with FIP. However, further investigation of a possible role of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": -11.515625,
            "text": ", itraconazole partly exerted a beneficial effect in a cat with FIP. However, further investigation of a possible role of itraconazole",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_28": [
        {
            "start_logit": 15.265625,
            "end_logit": 12.4140625,
            "text": "itraconazole",
            "probability": 1.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -5.55078125,
            "text": "itraconazole and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -9.7109375,
            "text": "itraconazole and",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -10.84375,
            "text": "itraconazole and prednisolone for treating effusive",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -11.234375,
            "text": "itraconazole and prednisolone for treating effusive feline infectious peritonitis",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -11.296875,
            "text": "itraconazole and prednisolone for treating effusive feline infectious peritonitis.",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -11.359375,
            "text": "itraconazole and prednisolone for treating eff",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -11.625,
            "text": "itraconazole and prednisolone for treating",
            "probability": 0.0
        },
        {
            "start_logit": 15.265625,
            "end_logit": -11.640625,
            "text": "itraconazole and prednisolone for",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 12.4140625,
            "text": "therapy of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": 12.4140625,
            "text": "Clinical efficacy of combination therapy of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 12.4140625,
            "text": "efficacy of combination therapy of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 12.4140625,
            "text": "combination therapy of itraconazole",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -5.55078125,
            "text": "prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": -5.55078125,
            "text": "therapy of itraconazole and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": -5.55078125,
            "text": "Clinical efficacy of combination therapy of itraconazole and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -5.55078125,
            "text": "and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -5.55078125,
            "text": "efficacy of combination therapy of itraconazole and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -5.55078125,
            "text": "combination therapy of itraconazole and prednisolone",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -10.84375,
            "text": "prednisolone for treating effusive",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_29": [
        {
            "start_logit": 11.7734375,
            "end_logit": 11.90625,
            "text": "GS-441524",
            "probability": 1.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 11.90625,
            "text": "24",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -6.98046875,
            "text": "GS-",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -7.14453125,
            "text": "GS-44",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -7.51953125,
            "text": "GS-4415",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -7.6796875,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 11.90625,
            "text": "441524",
            "probability": 0.0
        },
        {
            "start_logit": -8.4609375,
            "end_logit": 11.90625,
            "text": "1524",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 11.90625,
            "text": "analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 11.90625,
            "text": "-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 11.90625,
            "text": "nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 11.90625,
            "text": "the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 11.90625,
            "text": "Efficacy and safety of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -11.2421875,
            "text": "GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -11.4921875,
            "text": "GS-441524 for treatment",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -11.7578125,
            "text": "GS-441524 for",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -11.78125,
            "text": "GS-441524 for treatment of",
            "probability": 0.0
        },
        {
            "start_logit": 11.7734375,
            "end_logit": -11.9609375,
            "text": "GS-441524 for treatment of cats",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -7.14453125,
            "text": "44",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -7.51953125,
            "text": "4415",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_30": [
        {
            "start_logit": 10.078125,
            "end_logit": 10.4140625,
            "text": "GS-441524",
            "probability": 1.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 10.4140625,
            "text": "24",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 10.4140625,
            "text": "analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -7.515625,
            "text": "GS-",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 10.4140625,
            "text": "the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.25,
            "text": "GS-44",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 10.4140625,
            "text": "nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -8.4765625,
            "text": "GS",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 10.4140625,
            "text": "441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 10.4140625,
            "text": "-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 10.4140625,
            "text": "The aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 10.4140625,
            "text": "1524",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -9.28125,
            "text": "GS-4415",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 10.4140625,
            "text": "the safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 10.4140625,
            "text": "aim of this study was to determine the safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 10.4140625,
            "text": "this study was to determine the safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 10.4140625,
            "text": "to determine the safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 10.4140625,
            "text": "safety and efficacy of the nucleoside analog GS-441524",
            "probability": 0.0
        },
        {
            "start_logit": 10.078125,
            "end_logit": -11.9765625,
            "text": "GS-441524 for cats suffering from various forms of naturally acquired feline infectious peritonitis",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -7.515625,
            "text": "analog GS-",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_31": [
        {
            "start_logit": 14.015625,
            "end_logit": 14.03125,
            "text": "S-441524",
            "probability": 1.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -5.3359375,
            "text": "S-",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -5.70703125,
            "text": "S-4415",
            "probability": 0.0
        },
        {
            "start_logit": -6.00390625,
            "end_logit": 14.03125,
            "text": "24",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -6.0859375,
            "text": "S-44",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -6.3125,
            "text": "S",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 14.03125,
            "text": "441524",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": 14.03125,
            "text": "-441524",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 14.03125,
            "text": "1524",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.1640625,
            "text": "S-441524 was",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.515625,
            "text": "S-441524 was shown to be a safe and effective treatment for FIP. The optimum dosage was found to be 4.0 mg",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.5859375,
            "text": "S-441524 was shown to be a safe and effective treatment for FIP.",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.7578125,
            "text": "S-441524 was shown to be a safe and effective treatment for FIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.8984375,
            "text": "S-441524 was shown to be a safe",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -11.0390625,
            "text": "S-441524 was shown to be a safe and effective treatment for FI",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -11.140625,
            "text": "S-441524 was shown to be a",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -11.2109375,
            "text": "S-441524 was shown to be a safe and effective treatment for FIP. The",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -5.70703125,
            "text": "4415",
            "probability": 0.0
        },
        {
            "start_logit": -7.58984375,
            "end_logit": -5.3359375,
            "text": "-",
            "probability": 0.0
        },
        {
            "start_logit": -7.0546875,
            "end_logit": -6.0859375,
            "text": "44",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_32": [
        {
            "start_logit": 14.40625,
            "end_logit": 12.5390625,
            "text": "remdesivir",
            "probability": 1.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -5.83984375,
            "text": "rem",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -7.02734375,
            "text": "remdes",
            "probability": 0.0
        },
        {
            "start_logit": -6.0234375,
            "end_logit": 12.5390625,
            "text": "ivir",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": 12.5390625,
            "text": "desivir",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 12.5390625,
            "text": "effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 12.5390625,
            "text": "usive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -10.671875,
            "text": "remdesivir at 4.9-5.6 mg",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 12.5390625,
            "text": "with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 12.5390625,
            "text": "successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 12.5390625,
            "text": "FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 12.5390625,
            "text": "immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 12.5390625,
            "text": "monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -11.453125,
            "text": "remdesivir at 4.9-5.6 mg/kg daily",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 12.5390625,
            "text": "resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -11.5859375,
            "text": "remdesivir at 4.9-5.6 mg/kg daily for 80 days.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 12.5390625,
            "text": "This paper reports on the successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 12.5390625,
            "text": "cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -11.9296875,
            "text": "remdesivir at",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 12.5390625,
            "text": "the successful resolution of immunohistochemistry-confirmed effusive FIP in an adolescent cat in South Africa following monotherapy with remdesivir",
            "probability": 0.0
        }
    ],
    "64240f33690f196b51000049_33": [
        {
            "start_logit": 13.7890625,
            "end_logit": 11.8671875,
            "text": "remdesivir",
            "probability": 1.0
        },
        {
            "start_logit": -3.8046875,
            "end_logit": 11.8671875,
            "text": "uccessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -6.40625,
            "text": "rem",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -6.796875,
            "text": "remdes",
            "probability": 0.0
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 11.8671875,
            "text": "ivir",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -8.5234375,
            "text": "remdesivir.",
            "probability": 0.0
        },
        {
            "start_logit": -6.953125,
            "end_logit": 11.8671875,
            "text": "desivir",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 11.8671875,
            "text": "ful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": 11.8671875,
            "text": "cessful treatment of a South African cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -8.4375,
            "end_logit": 11.8671875,
            "text": "with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 11.8671875,
            "text": "usive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 11.8671875,
            "text": "effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 11.8671875,
            "text": "treatment of a South African cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 11.8671875,
            "text": "cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 11.8671875,
            "text": "feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.8671875,
            "text": "peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.8671875,
            "text": "South African cat with effusive feline infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 11.8671875,
            "text": "infectious peritonitis with remdesivir",
            "probability": 0.0
        },
        {
            "start_logit": -3.8046875,
            "end_logit": -3.9921875,
            "text": "uc",
            "probability": 0.0
        },
        {
            "start_logit": -3.8046875,
            "end_logit": -6.3828125,
            "text": "uccessful",
            "probability": 0.0
        }
    ],
    "6432fb1957b1c7a31500001e_0": [
        {
            "start_logit": 7.7734375,
            "end_logit": 6.3984375,
            "text": "mantle cell lymphoma",
            "probability": 0.998046875
        },
        {
            "start_logit": 1.5498046875,
            "end_logit": 6.3984375,
            "text": "treating adults with mantle cell lymphoma",
            "probability": 0.001979827880859375
        },
        {
            "start_logit": -3.068359375,
            "end_logit": 6.3984375,
            "text": "adults with mantle cell lymphoma",
            "probability": 1.9490718841552734e-05
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -5.9140625,
            "text": "mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -7.765625,
            "text": "mantle cell lymphoma who have received at least one prior therapy,",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 6.3984375,
            "text": "In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -8.4140625,
            "text": "mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia, and for adults with relapsed or refractory marginal",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.296875,
            "end_logit": 6.3984375,
            "text": "with mantle cell lymphoma",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.44140625,
            "end_logit": 6.3984375,
            "text": "has been approved for treating adults with mantle cell lymphoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 6.3984375,
            "text": ", zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 6.3984375,
            "text": "lymphoma",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -9.25,
            "text": "mantle cell lymphoma who",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -9.4375,
            "text": "mantle",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 6.3984375,
            "text": "the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 7.7734375,
            "end_logit": -9.7890625,
            "text": "mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenstr\u00f6m macroglobulinemia,",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 6.3984375,
            "text": "zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9375,
            "end_logit": 6.3984375,
            "text": "been approved for treating adults with mantle cell lymphoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 6.3984375,
            "text": "for treating adults with mantle cell lymphoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.515625,
            "end_logit": 6.3984375,
            "text": "approved for treating adults with mantle cell lymphoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 6.3984375,
            "text": "a next-generation BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
            "probability": 0.0
        }
    ],
    "6432fb1957b1c7a31500001e_1": [
        {
            "start_logit": 4.15234375,
            "end_logit": -2.638671875,
            "text": "treatment of adult patients with MCL",
            "probability": 0.6083984375
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -2.638671875,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL",
            "probability": 0.19677734375
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -4.19921875,
            "text": "treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM",
            "probability": 0.1278076171875
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -4.19921875,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM",
            "probability": 0.04132080078125
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -6.49609375,
            "text": "treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL",
            "probability": 0.012847900390625
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -7.98828125,
            "text": "treatment of adult patients with MCL who have received at least one prior therapy,",
            "probability": 0.0028858184814453125
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -8.1484375,
            "text": "treatment of adult patients with",
            "probability": 0.002468109130859375
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -8.546875,
            "text": "treatment",
            "probability": 0.00165557861328125
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -7.98828125,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have received at least one prior therapy,",
            "probability": 0.0009365081787109375
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -8.1484375,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients with",
            "probability": 0.0007948875427246094
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -9.3671875,
            "text": "treatment of adult patients",
            "probability": 0.0007295608520507812
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -9.6015625,
            "text": "treatment of adult patients with MCL who",
            "probability": 0.0005769729614257812
        },
        {
            "start_logit": -2.857421875,
            "end_logit": -2.638671875,
            "text": "use for treatment of adult patients with MCL",
            "probability": 0.0005502700805664062
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -8.546875,
            "text": "Zanubrutinib is currently approved for use for treatment",
            "probability": 0.0005335807800292969
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -9.6953125,
            "text": "treatment of adult",
            "probability": 0.0005254745483398438
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -9.9765625,
            "text": "treatment of",
            "probability": 0.00039649009704589844
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -9.3671875,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients",
            "probability": 0.00023484230041503906
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -9.6015625,
            "text": "Zanubrutinib is currently approved for use for treatment of adult patients with MCL who",
            "probability": 0.00018584728240966797
        },
        {
            "start_logit": 4.15234375,
            "end_logit": -10.7578125,
            "text": "treatment of adult patients with MCL who have received at least one prior therapy, for adults with",
            "probability": 0.00018143653869628906
        },
        {
            "start_logit": 3.0234375,
            "end_logit": -9.6953125,
            "text": "Zanubrutinib is currently approved for use for treatment of adult",
            "probability": 0.0001691579818725586
        }
    ],
    "6413712a201352f04a00003e_0": [
        {
            "start_logit": 11.71875,
            "end_logit": 10.65625,
            "text": "gliomas",
            "probability": 1.0
        },
        {
            "start_logit": 0.91015625,
            "end_logit": 10.65625,
            "text": "Lower grade gliomas",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -6.30078125,
            "end_logit": 10.65625,
            "text": "grade gliomas",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -8.0078125,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -8.8359375,
            "text": "gliomas (LGGs",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -9.625,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.3125,
            "text": "gliomas (LGGs)",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.5,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have a favorable outcome.",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.5859375,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 code",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -10.90625,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.1015625,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion)",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.21875,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.5546875,
            "text": "gliomas (",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.5625,
            "text": "gliomas (LGGs) with",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.734375,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.75,
            "text": "gliomas (LG",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.8984375,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p",
            "probability": 0.0
        },
        {
            "start_logit": 11.71875,
            "end_logit": -11.953125,
            "text": "gliomas (LGGs) with codeletion of chromosomal arms 1p and 19q (1p/19 codeletion) have",
            "probability": 0.0
        },
        {
            "start_logit": 0.91015625,
            "end_logit": -3.587890625,
            "text": "Lower",
            "probability": 0.0
        },
        {
            "start_logit": 0.91015625,
            "end_logit": -7.96484375,
            "text": "Lower grade",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_1": [
        {
            "start_logit": 14.6015625,
            "end_logit": 13.625,
            "text": "glioma",
            "probability": 1.0
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 13.625,
            "text": "diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -9.7421875,
            "text": "glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.9609375,
            "text": "glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -11.5546875,
            "text": "glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification.",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -11.6171875,
            "text": "glioma cases (grade 2, 56; grade 3, 62; grade 4, 182)",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -11.6875,
            "text": "glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the",
            "probability": 0.0
        },
        {
            "start_logit": -5.39453125,
            "end_logit": -6.8984375,
            "text": "diffuse",
            "probability": 0.0
        },
        {
            "start_logit": -7.2890625,
            "end_logit": -6.890625,
            "text": "glioma",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -6.890625,
            "text": "IDH) genes were common in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -5.39453125,
            "end_logit": -9.7421875,
            "text": "diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification. Mutations in the isocitrate dehydrogenase",
            "probability": 0.0
        },
        {
            "start_logit": -7.52734375,
            "end_logit": -7.80859375,
            "text": "ID",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": -6.890625,
            "text": "dehydrogenase (IDH) genes were common in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -6.890625,
            "text": "isocitrate dehydrogenase (IDH) genes were common in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -5.39453125,
            "end_logit": -10.9609375,
            "text": "diffuse glioma cases (grade 2, 56; grade 3, 62; grade 4, 182) based on this classification",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -6.890625,
            "text": "H) genes were common in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": -6.890625,
            "text": "grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -6.890625,
            "text": "the isocitrate dehydrogenase (IDH) genes were common in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -6.890625,
            "text": "in lower grade glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -6.890625,
            "text": "lower grade glioma",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_2": [
        {
            "start_logit": 14.8828125,
            "end_logit": 12.546875,
            "text": "Glioblastoma",
            "probability": 1.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -1.638671875,
            "text": "Glioblastoma remains a deadly brain cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -10.421875,
            "text": "Glioblastoma remains a deadly brain",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -11.96875,
            "text": "Glioblastoma remains",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.1171875,
            "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations,",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.171875,
            "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including ID",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.28125,
            "text": "Glioblastoma remains a",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.3671875,
            "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.4609375,
            "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH mutations,",
            "probability": 0.0
        },
        {
            "start_logit": 14.8828125,
            "end_logit": -12.484375,
            "text": "Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including IDH mutations, 1p19q co-deletion status",
            "probability": 0.0
        },
        {
            "start_logit": -5.71484375,
            "end_logit": -1.638671875,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -1.638671875,
            "text": "brain cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -1.638671875,
            "text": "deadly brain cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -1.638671875,
            "text": "a deadly brain cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -1.638671875,
            "text": "ly brain cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -1.638671875,
            "text": "remains a deadly brain cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.71484375,
            "end_logit": -12.1171875,
            "text": "cancer with dismal prognosis. Genetic alterations,",
            "probability": 0.0
        },
        {
            "start_logit": -5.71484375,
            "end_logit": -12.171875,
            "text": "cancer with dismal prognosis. Genetic alterations, including ID",
            "probability": 0.0
        },
        {
            "start_logit": -7.6171875,
            "end_logit": -10.421875,
            "text": "brain",
            "probability": 0.0
        },
        {
            "start_logit": -5.71484375,
            "end_logit": -12.3671875,
            "text": "cancer with dismal prognosis. Genetic alterations, including IDH",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_3": [
        {
            "start_logit": 15.8671875,
            "end_logit": 13.9296875,
            "text": "Oligodendroglioma",
            "probability": 1.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -3.658203125,
            "text": "Oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -5.60546875,
            "text": "Oligodendroglio",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -7.171875,
            "text": "Oligodendroglioma,",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -7.4609375,
            "text": "Oligodendroglioma, ID",
            "probability": 0.0
        },
        {
            "start_logit": -5.69140625,
            "end_logit": 13.9296875,
            "text": "ma",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -8.25,
            "text": "Oligodendroglioma, IDH-mutant",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 13.9296875,
            "text": "ioma",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -8.5234375,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q codeleted: 37",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -8.7734375,
            "text": "Oligodendroglioma, IDH-",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -8.8203125,
            "text": "Oligodendroglioma, IDH-mutant and 1p",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -9.015625,
            "text": "Oligodendroglioma, IDH",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -9.4609375,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q codeleted:",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -9.46875,
            "text": "Oligodendroglioma, IDH-mutant and",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -9.9375,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q codeleted",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -10.5703125,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q codeleted: 37;",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -10.6328125,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q code",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -10.65625,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q codelete",
            "probability": 0.0
        },
        {
            "start_logit": 15.8671875,
            "end_logit": -11.390625,
            "text": "Oligodendroglioma, IDH-mutant and 1p/19q",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": -5.60546875,
            "text": "io",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_4": [
        {
            "start_logit": 13.625,
            "end_logit": 12.21875,
            "text": "oligodendroglioma",
            "probability": 1.0
        },
        {
            "start_logit": 1.462890625,
            "end_logit": 12.21875,
            "text": "astrocytomas: Not everything that is co-deleted is an oligodendroglioma",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 0.54296875,
            "end_logit": 12.21875,
            "text": "fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 13.625,
            "end_logit": -5.63671875,
            "text": "oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": 13.625,
            "end_logit": -5.91796875,
            "text": "oligodendroglio",
            "probability": 0.0
        },
        {
            "start_logit": 1.462890625,
            "end_logit": 5.5234375,
            "text": "astrocytomas",
            "probability": 0.0
        },
        {
            "start_logit": 0.54296875,
            "end_logit": 5.5234375,
            "text": "fibrillary astrocytomas",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 12.21875,
            "text": "ioma",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 12.21875,
            "text": "ma",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": 12.21875,
            "text": "1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 13.625,
            "end_logit": -11.0859375,
            "text": "oligodendroglioma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 12.21875,
            "text": "thing that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.21875,
            "text": "an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 12.21875,
            "text": "Not everything that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 12.21875,
            "text": "everything that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.21875,
            "text": "/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.21875,
            "text": "co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.21875,
            "text": "ng that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.21875,
            "text": "deleted is an oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.21875,
            "text": "19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_5": [
        {
            "start_logit": 16.171875,
            "end_logit": 15.0,
            "text": "oligodendroglioma",
            "probability": 1.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -3.259765625,
            "text": "oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -5.421875,
            "text": "oligodendroglio",
            "probability": 0.0
        },
        {
            "start_logit": -5.6015625,
            "end_logit": 15.0,
            "text": "ma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -7.52734375,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": 15.0,
            "text": "ioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -8.34375,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 15.0,
            "text": "of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -8.5625,
            "end_logit": 15.0,
            "text": "1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -9.7578125,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System.",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -9.8046875,
            "text": "oligodendroglioma,",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 15.0,
            "text": "The presence of chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -10.1640625,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO) Classification",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 15.0,
            "text": "chromosome 1p/19q co-deletion is one of the hallmark required criteria for the diagnosis of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -10.1953125,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO)",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 15.0,
            "text": "the diagnosis of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 15.0,
            "text": "required criteria for the diagnosis of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -10.5859375,
            "text": "oligodendroglioma, using the",
            "probability": 0.0
        },
        {
            "start_logit": 16.171875,
            "end_logit": -10.6484375,
            "text": "oligodendroglioma, using the 2016 World Health Organization (WHO) Classification of",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 15.0,
            "text": "hallmark required criteria for the diagnosis of oligodendroglioma",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_6": [
        {
            "start_logit": 14.8984375,
            "end_logit": 12.8515625,
            "text": "glioblastomas",
            "probability": 1.0
        },
        {
            "start_logit": 5.87109375,
            "end_logit": 12.8515625,
            "text": "astrocytomas, primarily glioblastomas",
            "probability": 0.00011962652206420898
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -3.8984375,
            "text": "glioblastoma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.87109375,
            "end_logit": 2.69140625,
            "text": "astrocytomas",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": 12.8515625,
            "text": "primarily glioblastomas",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -7.9765625,
            "text": "glioblastomas, demonstrating partial losses on one or the other chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.15234375,
            "end_logit": 12.8515625,
            "text": "s",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -11.0234375,
            "text": "glioblastomas, demonstrating partial losses on",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -11.3203125,
            "text": "glioblastomas, demonstrating partial losses on one",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -11.4921875,
            "text": "glioblastomas, demonstrating partial losses on one or the other chromosome have been described.",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -11.5390625,
            "text": "glioblastomas, demonstrating",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -11.9453125,
            "text": "glioblastomas, demonstrating partial losses",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -12.1171875,
            "text": "glioblastomas, demonstrating partial losses on one or the other",
            "probability": 0.0
        },
        {
            "start_logit": 14.8984375,
            "end_logit": -12.1640625,
            "text": "glioblastomas, demonstrating partial losses on one or the other chromosome have",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 12.8515625,
            "text": "Descriptions in the literature of astrocytomas, primarily glioblastomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 12.8515625,
            "text": "the literature of astrocytomas, primarily glioblastomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.8515625,
            "text": "literature of astrocytomas, primarily glioblastomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.8515625,
            "text": "in the literature of astrocytomas, primarily glioblastomas",
            "probability": 0.0
        },
        {
            "start_logit": 5.87109375,
            "end_logit": -3.8984375,
            "text": "astrocytomas, primarily glioblastoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 12.8515625,
            "text": "of astrocytomas, primarily glioblastomas",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_7": [
        {
            "start_logit": 13.3828125,
            "end_logit": 4.62109375,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas",
            "probability": 0.8857421875
        },
        {
            "start_logit": 13.3828125,
            "end_logit": 2.24609375,
            "text": "Oligodendroglial tumours",
            "probability": 0.0823974609375
        },
        {
            "start_logit": 13.3828125,
            "end_logit": 1.2978515625,
            "text": "Oligodendroglial tumours (OT)",
            "probability": 0.032012939453125
        },
        {
            "start_logit": 3.12890625,
            "end_logit": 4.62109375,
            "text": "gliomas",
            "probability": 3.129243850708008e-05
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -6.08984375,
            "text": "Oligodendroglial",
            "probability": 1.990795135498047e-05
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -6.8046875,
            "text": "Oligodendrogl",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -7.02734375,
            "text": "Oligodendroglial tumours (OT) are",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -10.0390625,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -10.15625,
            "text": "Oligodendroglial tumours (",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.046875,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the ID",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.0703125,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.078125,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.4296875,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.515625,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -11.8984375,
            "text": "Oligodendroglial tumours (OT) are a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -12.0703125,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -12.15625,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3828125,
            "end_logit": -12.1953125,
            "text": "Oligodendroglial tumours (OT) are a heterogeneous group of gliomas. Three molecular subgroups are currently distinguished on the basis of the IDH mutation and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 4.62109375,
            "text": "ial tumours (OT) are a heterogeneous group of gliomas",
            "probability": 0.0
        },
        {
            "start_logit": -6.25390625,
            "end_logit": 4.62109375,
            "text": ") are a heterogeneous group of gliomas",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_8": [
        {
            "start_logit": -1.97265625,
            "end_logit": 10.375,
            "text": "three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system",
            "probability": 0.86474609375
        },
        {
            "start_logit": -4.55078125,
            "end_logit": 10.375,
            "text": "1p/19q co-deleted tumours, associated with specific expression patterns of nervous system",
            "probability": 0.0654296875
        },
        {
            "start_logit": -4.56640625,
            "end_logit": 10.375,
            "text": "nervous system",
            "probability": 0.06439208984375
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 10.375,
            "text": "system",
            "probability": 0.00473785400390625
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 10.375,
            "text": "tumours, associated with specific expression patterns of nervous system",
            "probability": 0.0003364086151123047
        },
        {
            "start_logit": -10.75,
            "end_logit": 10.375,
            "text": "within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system",
            "probability": 0.0001327991485595703
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 10.375,
            "text": "specific expression patterns of nervous system",
            "probability": 0.00011271238327026367
        },
        {
            "start_logit": -10.953125,
            "end_logit": 10.375,
            "text": "/19q co-deleted tumours, associated with specific expression patterns of nervous system",
            "probability": 0.00010848045349121094
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 10.375,
            "text": "19q co-deleted tumours, associated with specific expression patterns of nervous system",
            "probability": 0.00010102987289428711
        },
        {
            "start_logit": -11.09375,
            "end_logit": 10.375,
            "text": "expression patterns of nervous system",
            "probability": 9.417533874511719e-05
        },
        {
            "start_logit": -1.97265625,
            "end_logit": -0.912109375,
            "text": "three",
            "probability": 1.0848045349121094e-05
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": -4.94921875,
            "text": "oligodendrocyte precursor cell (OPC) and neuronal lineage.",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -1.97265625,
            "end_logit": -5.9921875,
            "text": "three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": -8.3203125,
            "text": "oligodendrocyte precursor cell (OPC) and neuronal lineage",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": -8.4453125,
            "text": "oligodendrocyte precursor cell (OPC",
            "probability": 0.0
        },
        {
            "start_logit": -1.97265625,
            "end_logit": -7.1015625,
            "text": "three subgroups within 1p/19q co-deleted tumours",
            "probability": 0.0
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": -8.9140625,
            "text": "oligodendrocyte",
            "probability": 0.0
        },
        {
            "start_logit": -4.56640625,
            "end_logit": -4.94921875,
            "text": "nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC) and neuronal lineage.",
            "probability": 0.0
        },
        {
            "start_logit": -0.53564453125,
            "end_logit": -9.640625,
            "text": "oligodendrocyte precursor cell (OPC)",
            "probability": 0.0
        },
        {
            "start_logit": -1.97265625,
            "end_logit": -8.4453125,
            "text": "three subgroups within 1p/19q co-deleted tumours, associated with specific expression patterns of nervous system cell types: oligodendrocyte, oligodendrocyte precursor cell (OPC",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_9": [
        {
            "start_logit": 14.546875,
            "end_logit": 13.3828125,
            "text": "gliomas",
            "probability": 1.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 13.3828125,
            "text": "diffuse gliomas",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.140625,
            "text": "gliomas into",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.34375,
            "text": "gliomas into three distinct molecular categories: chromosome 1p",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.4453125,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/ID",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.0234375,
            "text": "gliomas into three distinct molecular categories: chromosome",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.6875,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.8359375,
            "text": "gliomas into three distinct",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.8828125,
            "text": "gliomas into three distinct molecular categories",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.9140625,
            "text": "gliomas into three",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -11.921875,
            "text": "gliomas into three distinct molecular categories:",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -12.1640625,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant,",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -12.265625,
            "text": "gliomas into three distinct molecular",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -12.3125,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -12.3984375,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/IDH mutant",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -12.4140625,
            "text": "gliomas into three distinct molecular categories: chromosome 1p/19q",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -7.43359375,
            "text": "diffuse",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -10.140625,
            "text": "diffuse gliomas into",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -10.34375,
            "text": "diffuse gliomas into three distinct molecular categories: chromosome 1p",
            "probability": 0.0
        },
        {
            "start_logit": -5.94921875,
            "end_logit": -10.4453125,
            "text": "diffuse gliomas into three distinct molecular categories: chromosome 1p/19q co-deleted/ID",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_10": [
        {
            "start_logit": 16.140625,
            "end_logit": 15.015625,
            "text": "oligodendroglioma",
            "probability": 1.0
        },
        {
            "start_logit": 16.140625,
            "end_logit": -3.27734375,
            "text": "oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": 16.140625,
            "end_logit": -5.74609375,
            "text": "oligodendroglio",
            "probability": 0.0
        },
        {
            "start_logit": -5.625,
            "end_logit": 15.015625,
            "text": "ma",
            "probability": 0.0
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 15.015625,
            "text": "ioma",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 15.015625,
            "text": "of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": 15.015625,
            "text": "1p/19q is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.140625,
            "end_logit": -8.921875,
            "text": "oligodendroglioma and predicts better survival.",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 15.015625,
            "text": "Co-deletion of 1p/19q is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.140625,
            "end_logit": -10.328125,
            "text": "oligodendroglioma and predicts better survival",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 15.015625,
            "text": "a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": 16.140625,
            "end_logit": -10.625,
            "text": "oligodendroglioma and",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 15.015625,
            "text": "is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 15.015625,
            "text": "hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 15.015625,
            "text": "19q is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.015625,
            "text": "of 1p/19q is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.015625,
            "text": "-deletion of 1p/19q is a hallmark of oligodendroglioma",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": -3.27734375,
            "text": "of oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": -7.77734375,
            "end_logit": -3.27734375,
            "text": "1p/19q is a hallmark of oligodendrogl",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -3.27734375,
            "text": "Co-deletion of 1p/19q is a hallmark of oligodendrogl",
            "probability": 0.0
        }
    ],
    "6413712a201352f04a00003e_11": [
        {
            "start_logit": 13.2734375,
            "end_logit": 13.84375,
            "text": "glioma",
            "probability": 1.0
        },
        {
            "start_logit": -3.734375,
            "end_logit": 13.84375,
            "text": "diffuse glioma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.046875,
            "end_logit": 13.84375,
            "text": "IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 13.84375,
            "text": "is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 13.84375,
            "text": "second is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 13.84375,
            "text": "1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.84375,
            "text": "H mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 13.84375,
            "text": "sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.84375,
            "text": "examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 13.84375,
            "text": "/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.84375,
            "text": "19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.84375,
            "text": "own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 13.84375,
            "text": "their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.84375,
            "text": "the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.84375,
            "text": "co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse glioma",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -11.875,
            "text": "glioma patients.",
            "probability": 0.0
        },
        {
            "start_logit": -3.734375,
            "end_logit": -6.07421875,
            "text": "diffuse",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": -6.07421875,
            "text": "IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse",
            "probability": 0.0
        },
        {
            "start_logit": -3.734375,
            "end_logit": -11.875,
            "text": "diffuse glioma patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -6.07421875,
            "text": "is that examinations for IDH mutations and 1p/19q co-deletion are not sufficient on their own to accurately predict the prognosis of diffuse",
            "probability": 0.0
        }
    ]
}
